WO2015006875A1 - Procédé de préparation de pyrimidines substituées - Google Patents
Procédé de préparation de pyrimidines substituées Download PDFInfo
- Publication number
- WO2015006875A1 WO2015006875A1 PCT/CA2014/050684 CA2014050684W WO2015006875A1 WO 2015006875 A1 WO2015006875 A1 WO 2015006875A1 CA 2014050684 W CA2014050684 W CA 2014050684W WO 2015006875 A1 WO2015006875 A1 WO 2015006875A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- group
- hydrocarbyl
- compound
- acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 110
- 230000008569 process Effects 0.000 title claims abstract description 93
- 238000002360 preparation method Methods 0.000 title description 6
- 150000003230 pyrimidines Chemical class 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 171
- -1 amino, hydroxy Chemical group 0.000 claims description 122
- 239000002253 acid Substances 0.000 claims description 119
- 239000011541 reaction mixture Substances 0.000 claims description 107
- 125000000623 heterocyclic group Chemical group 0.000 claims description 84
- 125000003118 aryl group Chemical group 0.000 claims description 77
- 238000006243 chemical reaction Methods 0.000 claims description 74
- 150000002148 esters Chemical class 0.000 claims description 64
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 57
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 53
- 125000001072 heteroaryl group Chemical group 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 51
- 125000001424 substituent group Chemical group 0.000 claims description 47
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 38
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 34
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 30
- 238000004519 manufacturing process Methods 0.000 claims description 30
- 238000000746 purification Methods 0.000 claims description 29
- 125000006239 protecting group Chemical group 0.000 claims description 27
- 229920006395 saturated elastomer Polymers 0.000 claims description 22
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 21
- 125000003386 piperidinyl group Chemical group 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 17
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 claims description 16
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 125000005549 heteroarylene group Chemical group 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 102000003964 Histone deacetylase Human genes 0.000 claims description 11
- 108090000353 Histone deacetylase Proteins 0.000 claims description 11
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 11
- 125000006242 amine protecting group Chemical group 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000002252 acyl group Chemical group 0.000 claims description 8
- 150000001448 anilines Chemical class 0.000 claims description 8
- 125000000732 arylene group Chemical group 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 150000001266 acyl halides Chemical class 0.000 claims description 3
- 150000008064 anhydrides Chemical class 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000010511 deprotection reaction Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims 2
- MYDIPHROYRTYRS-UHFFFAOYSA-N n-(2-aminophenyl)-4-[(pyrimidin-2-ylamino)methyl]benzamide Chemical class NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC=N1 MYDIPHROYRTYRS-UHFFFAOYSA-N 0.000 abstract description 26
- 239000000543 intermediate Substances 0.000 abstract description 12
- 239000012467 final product Substances 0.000 abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 108
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 101
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 69
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 60
- 239000002904 solvent Substances 0.000 description 57
- MGBACQHHWFZAEW-UHFFFAOYSA-N 4-[(pyrimidin-2-ylamino)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CNC1=NC=CC=N1 MGBACQHHWFZAEW-UHFFFAOYSA-N 0.000 description 43
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 35
- 239000000243 solution Substances 0.000 description 35
- 238000010992 reflux Methods 0.000 description 33
- 150000003839 salts Chemical class 0.000 description 33
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 32
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 29
- 238000001953 recrystallisation Methods 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- DCGMAVMKRIYBBH-UHFFFAOYSA-N methyl 4-[(pyrimidin-2-ylamino)methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CNC1=NC=CC=N1 DCGMAVMKRIYBBH-UHFFFAOYSA-N 0.000 description 27
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 26
- 238000010438 heat treatment Methods 0.000 description 26
- 238000001914 filtration Methods 0.000 description 25
- 229910052757 nitrogen Inorganic materials 0.000 description 25
- 239000000725 suspension Substances 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 21
- 125000000392 cycloalkenyl group Chemical group 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 17
- 239000002244 precipitate Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 16
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 16
- 238000005580 one pot reaction Methods 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 14
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- RUSQUIYMDUXKSM-UHFFFAOYSA-N methyl 4-[(diaminomethylideneamino)methyl]benzoate Chemical compound COC(=O)C1=CC=C(CNC(N)=N)C=C1 RUSQUIYMDUXKSM-UHFFFAOYSA-N 0.000 description 14
- 125000002947 alkylene group Chemical group 0.000 description 13
- 125000005843 halogen group Chemical group 0.000 description 13
- 238000000967 suction filtration Methods 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- ZWKIKIJKGFTAAM-UHFFFAOYSA-N 4-[(diaminomethylideneamino)methyl]benzoic acid Chemical compound NC(N)=NCC1=CC=C(C(O)=O)C=C1 ZWKIKIJKGFTAAM-UHFFFAOYSA-N 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 230000002378 acidificating effect Effects 0.000 description 11
- 125000003342 alkenyl group Chemical group 0.000 description 11
- 125000001544 thienyl group Chemical group 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 125000000304 alkynyl group Chemical group 0.000 description 10
- 125000004093 cyano group Chemical group *C#N 0.000 description 10
- GIZCKBSSWNIUMZ-UHFFFAOYSA-N methyl 4-(aminomethyl)benzoate;hydrochloride Chemical compound Cl.COC(=O)C1=CC=C(CN)C=C1 GIZCKBSSWNIUMZ-UHFFFAOYSA-N 0.000 description 10
- 239000003960 organic solvent Substances 0.000 description 10
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 10
- 125000004076 pyridyl group Chemical group 0.000 description 10
- 125000000714 pyrimidinyl group Chemical group 0.000 description 10
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 9
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 9
- MZLRFUCMBQWLNV-FNORWQNLSA-N (e)-3-(dimethylamino)-1-pyridin-3-ylprop-2-en-1-one Chemical compound CN(C)\C=C\C(=O)C1=CC=CN=C1 MZLRFUCMBQWLNV-FNORWQNLSA-N 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 8
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 8
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
- 150000001204 N-oxides Chemical class 0.000 description 8
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 8
- 150000007530 organic bases Chemical class 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 230000020477 pH reduction Effects 0.000 description 8
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 7
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000009835 boiling Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 125000004043 oxo group Chemical group O=* 0.000 description 7
- 239000012453 solvate Substances 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 0 *N(*)C=CC(C1CCCCCCCCC1)=O Chemical compound *N(*)C=CC(C1CCCCCCCCC1)=O 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 6
- 239000012296 anti-solvent Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 6
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- WTKURPVKNVDIFM-UHFFFAOYSA-N 4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 WTKURPVKNVDIFM-UHFFFAOYSA-N 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 125000002883 imidazolyl group Chemical group 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 229910052744 lithium Inorganic materials 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 125000000547 substituted alkyl group Chemical group 0.000 description 5
- 150000003512 tertiary amines Chemical class 0.000 description 5
- 238000001665 trituration Methods 0.000 description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 4
- ZJSQZQMVXKZAGW-UHFFFAOYSA-N 2H-benzotriazol-4-ol hydrate Chemical compound O.OC1=CC=CC2=C1N=NN2 ZJSQZQMVXKZAGW-UHFFFAOYSA-N 0.000 description 4
- WEGYGNROSJDEIW-UHFFFAOYSA-N 3-Acetylpyridine Chemical compound CC(=O)C1=CC=CN=C1 WEGYGNROSJDEIW-UHFFFAOYSA-N 0.000 description 4
- IQKLOQHWKQYTQZ-UHFFFAOYSA-N 4-(aminomethyl)benzoic acid;hydrochloride Chemical compound Cl.NCC1=CC=C(C(O)=O)C=C1 IQKLOQHWKQYTQZ-UHFFFAOYSA-N 0.000 description 4
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 4
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 125000004404 heteroalkyl group Chemical group 0.000 description 4
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 4
- 125000000842 isoxazolyl group Chemical group 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 125000003367 polycyclic group Polymers 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 125000003373 pyrazinyl group Chemical group 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 239000011343 solid material Substances 0.000 description 4
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- JZGHSXBVKSMAKH-VMPITWQZSA-N (e)-3-(dimethylamino)-1-pyridin-4-ylprop-2-en-1-one Chemical compound CN(C)\C=C\C(=O)C1=CC=NC=C1 JZGHSXBVKSMAKH-VMPITWQZSA-N 0.000 description 3
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 3
- BOCQEKBKBUOBCR-UHFFFAOYSA-N 4-(2-methyliminohydrazinyl)benzoic acid Chemical compound CN=NNC1=CC=C(C(O)=O)C=C1 BOCQEKBKBUOBCR-UHFFFAOYSA-N 0.000 description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 3
- 125000004442 acylamino group Chemical group 0.000 description 3
- 125000002877 alkyl aryl group Chemical group 0.000 description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000000010 aprotic solvent Substances 0.000 description 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 125000000160 oxazolidinyl group Chemical group 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 125000005493 quinolyl group Chemical group 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 2
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 2
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 2
- RBZRMBCLZMEYEH-UHFFFAOYSA-N 1h-pyrazol-1-ium-1-carboximidamide;chloride Chemical compound Cl.NC(=N)N1C=CC=N1 RBZRMBCLZMEYEH-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000001118 alkylidene group Chemical group 0.000 description 2
- 125000004419 alkynylene group Chemical group 0.000 description 2
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 239000011260 aqueous acid Substances 0.000 description 2
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000003943 azolyl group Chemical group 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-VQEHIDDOSA-N benzoic acid Chemical compound OC(=O)C1=CC=C[13CH]=C1 WPYMKLBDIGXBTP-VQEHIDDOSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
- 125000005518 carboxamido group Chemical group 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- PQANGXXSEABURG-UHFFFAOYSA-N cyclohex-2-en-1-ol Chemical compound OC1CCCC=C1 PQANGXXSEABURG-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000012973 diazabicyclooctane Substances 0.000 description 2
- 125000004987 dibenzofuryl group Chemical group C1(=CC=CC=2OC3=C(C21)C=CC=C3)* 0.000 description 2
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010931 ester hydrolysis Methods 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000759 toxicological effect Toxicity 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 description 1
- BWKAYBPLDRWMCJ-UHFFFAOYSA-N 1,1-diethoxy-n,n-dimethylmethanamine Chemical compound CCOC(N(C)C)OCC BWKAYBPLDRWMCJ-UHFFFAOYSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- WMQUKDQWMMOHSA-UHFFFAOYSA-N 1-pyridin-4-ylethanone Chemical compound CC(=O)C1=CC=NC=C1 WMQUKDQWMMOHSA-UHFFFAOYSA-N 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000006087 2-oxopyrrolodinyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 125000004610 3,4-dihydro-4-oxo-quinazolinyl group Chemical group O=C1NC(=NC2=CC=CC=C12)* 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical class OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- WPDAVTSOEQEGMS-UHFFFAOYSA-N 9,10-dihydroanthracene Chemical compound C1=CC=C2CC3=CC=CC=C3CC2=C1 WPDAVTSOEQEGMS-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000004411 C5-C6 heterocyclyl group Chemical group 0.000 description 1
- AQBJGAUQEJFPKZ-UHFFFAOYSA-N COC(c1ccc(CN)cc1)=O Chemical compound COC(c1ccc(CN)cc1)=O AQBJGAUQEJFPKZ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005116 aryl carbamoyl group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 229940054066 benzamide antipsychotics Drugs 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- ALMQNZNREIHKET-UHFFFAOYSA-N benzoic acid;dihydrate Chemical compound O.O.OC(=O)C1=CC=CC=C1 ALMQNZNREIHKET-UHFFFAOYSA-N 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005512 benztetrazolyl group Chemical group 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000005569 butenylene group Chemical group 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005622 butynylene group Chemical group 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229920001577 copolymer Chemical group 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohex-2-enone Chemical compound O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- BFAIMMGBWGSCPF-UHFFFAOYSA-N cyclopenta-1,4-dien-1-ol Chemical compound OC1=CCC=C1 BFAIMMGBWGSCPF-UHFFFAOYSA-N 0.000 description 1
- FQQOMPOPYZIROF-UHFFFAOYSA-N cyclopenta-2,4-dien-1-one Chemical group O=C1C=CC=C1 FQQOMPOPYZIROF-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000004609 dihydroquinazolinyl group Chemical group N1(CN=CC2=CC=CC=C12)* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000004615 furo[2,3-b]pyridinyl group Chemical group O1C(=CC=2C1=NC=CC2)* 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 description 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- NTRZTEIRFMYHSU-UHFFFAOYSA-N methyl 4-[(diaminomethylideneamino)methyl]benzoate;dihydrate Chemical compound O.O.COC(=O)C1=CC=C(CNC(N)=N)C=C1 NTRZTEIRFMYHSU-UHFFFAOYSA-N 0.000 description 1
- NNBBQNFHCVVQHZ-UHFFFAOYSA-N methyl carbamimidothioate;sulfuric acid Chemical compound CSC(N)=N.OS(O)(=O)=O NNBBQNFHCVVQHZ-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MUMVIYLVHVCYGI-UHFFFAOYSA-N n,n,n',n',n",n"-hexamethylmethanetriamine Chemical compound CN(C)C(N(C)C)N(C)C MUMVIYLVHVCYGI-UHFFFAOYSA-N 0.000 description 1
- YQVFMOOCVPMFER-UHFFFAOYSA-N n-(2-aminophenyl)-4-[[pyridin-3-yl(pyrimidin-2-yl)amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CN(C=1N=CC=CN=1)C1=CC=CN=C1 YQVFMOOCVPMFER-UHFFFAOYSA-N 0.000 description 1
- RFDVMOUXHKTCDO-UHFFFAOYSA-N n-(2-aminophenyl)benzamide Chemical compound NC1=CC=CC=C1NC(=O)C1=CC=CC=C1 RFDVMOUXHKTCDO-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000005593 norbornanyl group Chemical group 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical class CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 125000004928 piperidonyl group Chemical group 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
Definitions
- This invention relates to an improved process of making substituted pyrimidines and synthetic intermediates thereof.
- the invention relates to an improved process to prepare N-(2-aminophenyl)-4-((pyrimidin-2-ylamino)methyl)benzamides.
- this invention relates to an improved process of making N-(2-ammophenyl)-4-((4-pyridin-3- yl)pyrimidin-2-ylamino)methyl)benzamide that requires fewer steps, is efficient, can be used on an industrial scale, and results in a final product that is suitable for pharmaceutical use.
- Histone deacetylases constitute a family of enzymes that deacetylate histones and other cellular proteins. They are major regulators of transcription and are also important in other cellular processes. HDAC inhibition is a validated approach in cancer therapy, as evidenced by encouraging clinical data from various HDAC inhibitors. Moreover, preclinical proof-of-concept studies are emerging from animal models for non-oncologic diseases, including inflammatory and neurodegenerative diseases.
- N-(2-aminophenyl)-4-((pyrimidin-2-ylamino)methyl)benzamides are known to be useful as inhibitors of histone deacetylases and possess valuable pharmacological properties.
- MGCD0103 MetalGene Inc.
- one such compound in clinical trials has been shown to be useful in the treatment of cell proliferative diseases such as Hodgkin Lymphoma, non-Hodgkin Lymphoma, leukemia and solid tumors (e.g., Bonfils et al., Clin Cancer Res.
- the present invention provides an improved process for preparing HDAC inhibitors based on substiuted pyrimindines of Formula (I):
- Cy is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted and each of which is optionally fused to one or two aryl or heteroaryl rings, or to one or two saturated or partially unsaturated cycloalkyl or heterocyclic rings, each of which rings is also optionally substituted, for example, by 1-4 substituents independently selected form the group consisting of H, halo, cyano, nitro, Q-Csalkyl, Ci-C 3 alkoxy, Ci-Qalkylamino-, C ⁇ - C 3 dialkylamino-, Ci-C 3 alkylthio-, CF 3 , CHF 2 , CH 2 F, OH, NH 2 , -NHAc, -NH(CO)0-C 1 -C 3 alkyl, -CONH 2 , -CO-NH-Ci-C 3 alkyl, -CON(C 1 -C 3 alkyl) 2
- cycloalkyl, aryl, heteroaryl and heterocyclyl wherein said cycloalkyl, aryl, heteroary and heterocyclyl are themselves optionally substituted, for example by 1-4 substituents independently selected from the group consisting of H, halo, cyano, nitro, Ci-C 3 -alkyl, Q-C 3 - alkoxy, C 1 -C 3 -alkylamino-, Q-C dialkylamino-, Ci-C 3 -alkylthio-, CF 3 , CHF 2 , CH 2 F, OH, NH 2 , NHAc, NH(CO)0-Ci-C 3 -alkyl, NH(CO)NH- Ci-C 3 -alkyl. NH(CO)N(Cj-C 3 -alkyl) 2
- X is selected from the group consisting of a covalent bond, M -L -M , and L -M -L ;
- L 2 at each occurrence, is independently selected from the group consisting of a chemical bond, Co -4 hydrocarbyl, C 0-4 hydrocarbyl-(NH)-Co- 4 hydrocarbyl, C0-4 hydrocarbyl-S- C0-4 hydrocarbyl, and Co_ 4 hydrocarbyl-(0)-Co- 4 hydrocarbyl;
- M 1 at each occurrence, is independently selected from the group consisting of a chemical bond, -0-, -N(R 7 )-, -S-, -S(O)-, -S0 2 -, -S0 2 N(R 7 )-, -N(R 7 )-S0 2 -, -C(O)-, -C(0)-NH-, -NH-C(O)-, -NH-C(0)-0- and -0-C(0)-NH-;
- R 7 is selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, acyl, heterocyclyl, and heteroaryl;
- M is selected from the group consisting of M , heteroarylene, and heterocyclyl ene, either of which rings optionally is substituted;
- Ar is arylene or heteroarylene, each of which is optionally substituted
- Ay is a 5 to 6 membered aryl, or heteroaryl substituted with a substituent selected from the group consisting of amino, hydroxy, and -NH-PG, wherein PG is an amine protecting to the point of attachment of Ay to
- Ay is further optionally substituted.
- Ay is a 5 to 6 membered aryl substituted with a substituent selected from the group consisting of amino, hydroxy, and -NH-PG, wherein PG is an amine protecting group, which substituent is at a position ortho to the point of attacliment of Ay to
- Ay is further optionally substituted.
- Ay is a 5 to 6 membered aryl substituted with a substituent selected from the group consisting of amino, hydroxy, and -NH-PG, wherein PG is an amine protecting group, which substituent is at a position ortho to the point of attachment of Ay to
- Ay is further optionally substituted with a halo (for example F), phenyl, optionally substituted phenyl or thienyl.
- a halo for example F
- phenyl optionally substituted phenyl or thienyl.
- PG is selected from the group consisting of tert-butoxycarbonyl (Boc), F-Moc, benzyloxycarbonyl (Cbz), -COCF 3 , -CH 2 Ph and -C(0)Me.
- Ay is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- PG is a protecting group, selected from the group consisting of tert- butoxycarbonyl (Boc), F-Moc, benzyloxycarbonyl (Cbz), -COCF 3 , -CH 2 Ph, -C(0)Me,
- the present invention provides an improved process for preparing N-(2-aminophen -4-((pyrimidin-2-ylamino)methyl)benzamides of Formula (la):
- the present invention further provides improved processes for preparing intermediates used in the process for preparing compounds of Formula (I).
- the present invention further provides improved processes for preparing intermediates used in the process for preparing N-(2-aminophenyl)-4-((pyrimidin- 2-ylamino)methyl)benzamides of Formula (la).
- the present invention provides a process for preparing compounds of Formula (I) as defined abov
- R 10 is selected from the group consisting of amino, hydroxy, and -NH-PG, wherein PG is an amine protecting group;
- R 11 is an optional substituent, for example H, halo (for example F), phenyl, optionally substituted phenyl or thienyl,
- separating the acid of Formula (VII) so prepared comprises collecting the acid by filtration.
- the compound of Formula (V) is not previously purified from the reaction mixture in which it was prepared.
- the ester of Formula (VI) is not purified from the reaction mixture in which it was prepared prior to converting it to the acid of Formula (VII).
- the compound of Formula (V) is not previously purified from the reaction mixture in which it was prepared and the ester of Formula (VI) is not purified from the reaction mixture in which it was prepared prior to converting it to the acid of Formula (VII).
- the compound of Formula (V) is previously purified from the reaction mixture in which it was prepared.
- the ester of Formula (VI) is purified from the reaction mixture in which it was prepared prior to converting it to the acid of Formula (VII).
- the compound of Formula (V) is not previously purified from the reaction mixture in which it was prepared and the ester of Formula (VI) is purified from the reaction mixture in which it was prepared prior to converting it to the acid of Formula (VII). In certain embodiments of the first aspect, the compound of Formula (V) is previously purified from the reaction mixture in which it was prepared and the ester of Formula (VI) is purified from the reaction mixture in which it was prepared prior to converting it to the acid of Formula (VII).
- the process optionally further comprises purifying the compounds of Formula (I) so prepared.
- purification include recrystallization or titruration of the compounds of Formula (I) so prepared.
- the purifying comprises recrystallization.
- the present invention provides a process for preparing an N-(2-aminophenyl)-4-((pyrimidin-2-ylamino)methyl)benzamide of Formula (la) as defined above
- Conversion of the ester of Formula (Via) to the acid of Formula (Vila) results in a separable acid of Formula (Vila), which is used in the subsequent reaction step.
- separating the acid of Fomiula (Vila) so prepared comprises collecting the acid by filtration.
- the compound of Formula (Va) is not previously purified from the reaction mixture in which it was prepared.
- the 4-((pyrimidin-2- ylamino)methyl)benzoic acid alkyl ester of Formula (Via) is not purified prior to converting it to the 4-((pyrimidin-2-yl-amino)methyl)benzoic acid of Formula (Vila).
- the compound of Formula (Va) is not previously purified from the reaction mixture in which it was prepared and the 4-((pyrimidin-2- ylamino)methyl)benzoic acid alkyl ester of Formula (Via) is not purified from the reaction mixture in which it was prepared prior to converting it to the 4-((pyrimidin-2-yl- amino)methyl)benzoic acid of Formula (Vila).
- the compound of Formula (Va) is previously purified from the reaction mixture in which it was prepared.
- the 4-((pyrimidin-2- ylamino)methyl)benzoic acid alkyl ester of Formula (Via) is purified from the reaction mixture in which it was prepared prior to converting it to the 4-((pyrimidin-2-yl-amino)methyl)benzoic acid of Formula (Vila).
- the compound of Formula (Va) is not previously purified from the reaction mixture in which it was prepared and the 4-((pyrimidin-2- ylamino)methyl)benzoic acid alkyl ester of Formula (Via) is purified from the reaction mixture in which it was prepared prior to converting it to the 4-((pyrimidin-2-yl-amino)methyl)benzoic acid of Formula (Vila).
- the compound of Formula (Va) is previously purified from the reaction mixture in which it was prepared and the 4-((pyrimidin-2- ylamino)methyl)benzoic acid alkyl ester of Formula (Via) is purified from the reaction mixture in which it was prepared prior to converting it to the 4-((pyrimidin-2-yl-amiiio)niethyl)benzoic acid of Formula (Vila).
- the process optionally further comprises purifying the N-(2-aminophenyl)-4-((pyrimidin-2-ylamiiio)methyl)benzamide of Formula (la) so prepared.
- purification include crystallization or titruration of the N-(2- aminophenyl)-4-((pyrimidin-2-ylamino)methyl)benzamide of Formula (la) so prepared.
- the purifying comprises crystallization.
- the present invention provides a process for preparing a compound of Formula (I)
- R 10 is selected from the group consisting of amino, hydroxy, and -NH-PG, wherein PG is an amine protecting group;
- R 11 is an optional substituent, for example H, halo (for example F), phenyl or t ienyl.
- Conversion of the ester of Formula (VI) to the acid of Formula (VII) results in a separable acid of Formula (VII), which is used in the subsequent reaction step.
- separating the acid of Formula (VII) so prepared comprises collecting the acid by filtration.
- the process optionally further comprises purifying the compounds of Formula (I) so prepared.
- purification include recrystallization or titruration of the compounds of Formula (I) so prepared.
- the purification comprises recrystallization.
- the present invention provides a process for preparing an N-(2-aminophenyl)-4-((pyrimidin-2-ylamino)methyl)benzamide of Formula (la)
- Conversion of the ester of Formula (Via) to the acid of Formula (Vila) results in a separable acid of Formula (Vila), which is used in the subsequent reaction step.
- separating the acid of Formula (Vila) so prepared comprises collecting the acid by filtration.
- the process optionally further comprises purifying the N-(2- aminophenyl)-4-((pyrimidin-2-ylamino)methyl)benzamide of Formula (la) so prepared.
- purification include recrystallization or titruration of the N-(2-aminophenyl)-4- ((pyrimidin-2-ylamino)methyl)benzamide of Formula (la) so prepared.
- the purification comprises recrystallization.
- the present invention provides a process for preparing an acid of Formula (VII),
- the process optionally further comprises separating the acid of Formula (VII) so prepared from the reaction mixture.
- separating the acid of Formula (VII) so prepared comprises collecting the acid by filtration.
- the ester of Formula (VI) is not purified prior to converting it to the acid (VII).
- the ester of Formula (VI) is purified prior to converting it to the acid of Formula (VII).
- purification include recrystallization or titruration.
- the purifying comprises recrystallization.
- the invention optionally provides a "one- pot" process for preparing an acid of Formula (VII), the process comprising (a) reacting a compound of Formula (IV) x
- the process optionally further comprises separating the acid of Formula (VII) so prepared from the reaction mixture.
- separating the acid of Formula (VII) so prepared comprises collecting the acid by filtration.
- the present invention provides a process for preparing a 4-((pyrimidin- -yl-amino)methyl)benzoic acid of Formula (Vila),
- the 4-((pyrimidin-2- ylamino)methyl)benzoic acid methyl ester of Fomiula (Via) is not purified prior to converting it to the 4-((pyrimidin-2-yl-amino)methyl)benzoic acid (Vila).
- the 4-((pyrimidin-2- ylamino)methyl)benzoic acid methyl ester of Formula (Via) is purified prior to converting it to the 4-((pyrimidin-2-yl-amino)methyl)benzoic acid (Vila).
- purification include recrystallization or titruration.
- the purifying comprises recrystallization.
- the invention optionally provides a "one-pot" process for preparing a 4-((pyrimidin-2-yl- amino)methyl)benzoic acid of Formula (Vila), the process comprising (a) reacting a methyl 4- (aminomethyl)benzoate hydrochloride of Formula (IVa) (IVa)
- the process optionally further comprises separating the acid of Formula (Vila) so prepared from the reaction mixture.
- separating the acid of Formula (Vila) so prepared comprises collecting the acid by filtration.
- the present invention provides a process for preparing an acid of Formula (VII),
- the ester of Formula (VI) is not purified prior to converting it to the acid (VII).
- the ester of Formula (VI) is purified prior to converting it to the acid (VII).
- purification include recrystallization or titruration.
- the purifying comprises recrystallization.
- the process optionally further comprises separating the acid of Formula (VII) so prepared from the reaction mixture.
- separating the acid of Formula (VII) so prepared comprises collecting the acid by filtration.
- the present invention provides a process for preparing a 4-((pyrimidin- -yl-amino)methyl)benzoic acid of Formula (Vila),
- the 4-((pyrimidin-2- ylamino)methyl)benzoic acid methyl ester of Formula (Via) is not purified prior to converting it to the 4-((pyrimidin-2-yl-amino)methyl)benzoic acid (Vila).
- the 4-((pyrimidin-2- ylamino)methyl)benzoic acid methyl ester of Formula (Via) is purified prior to converting it to the 4-((pyrimidin-2-yl-amino)methyl)benzoic acid (Vila).
- purification include crystallization or titruration.
- the purifying comprises crystallization.
- the process optionally further comprises separating the acid of Formula (Vila) so prepared from the reaction mixture.
- separating the acid of Formula (Vila) so prepared comprises collecting the acid by filtration.
- the invention provides a process for preparing an enaminoketone of Formula (III),
- R and R are independently a C 1-4 alkyl, or R and R , together with the N to which they are attached form a ring structure selected from the group consisting of piperidine, pyrrolidine and morpholine, and R 3 and R 4 are independently a C 1-4 alkyl.
- R 1 , R 2 , R 3 and R 4 are not all Me.
- the present invention provides a process for preparing an ester of
- the invention optionally provides a "one- pot" process for preparing an ester of Foraiula (VI), the process comprising (a) reacting a compound of Formula (IV) with a guanidinylating agent under conditions that yield a compound of Fomiula (V); (b) reacting the compound of Foraiula (V) so prepared with an enaminoketone (III), to form an ester of Formula (VI); without purification of the compound of Formula (V) from the reaction mixture to prepare it prior to reaction with the enaminoketone of Formula (III).
- the present invention provides a process for preparing a 4-((pyrimidi -2-ylamino)methyl)benzoic acid methyl ester of Formula (Via),
- the invention optionally provides a "one-pot" process for preparing a 4-((pyrimidin-2-ylamino)methyl)benzoic acid methyl ester of Formula (Via), the process comprising (a) reacting a methyl 4- (aminomethyl)benzoate hydrochloride of Formula (IVa) with a guanidinylating agent under conditions that yield a 4-(guanidinomethyl)benzoate of Formula (Va); (b) reacting the 4- (guanidinomethyl)benzoate of Formula (Va) so prepared with an enaminoketone (III), to form a 4-((pyrimidin-2-ylamino)methyl)benzoic acid methyl ester of Formula (Via); without purification of the 4-(guanidinomethyl)benzoate of Formula (Va) from the reaction mixture to prepare it prior to reaction with the enaminoketone of Formula (III).
- the 4-((pyrimidin-2- ylamino)methyl)benzoic acid methyl ester of Formula (Via) is not purified from the reaction used to prepare it.
- the 4-((pyrimidin-2- ylamino)methyl)benzoic acid methyl ester of Formula (Via) is purified from the reaction used to prepare it.
- purification include recrystallization or trituration.
- the purifying comprises trituration.
- the invention provides a composition comprising a compound prepared according to any of the first or second aspects (including all embodiments thereof) and a pharmaceutically acceptable carrier.
- the composition is a medicament for treating a disease responsive to inhibition of a histone deacetylase.
- the disease responsive to inhibition of a histone deacetylase is a cell proliferative disease, such as, for example, cancer.
- the invention provides the use of a compound prepared according to the first or second aspect (including all embodiments thereof) in the manufacture of a medicament for treating a disease responsive to inhibition of a histone deacetylase.
- the disease responsive to inhibition of a histone deacetylase is a cell proliferative disease, such as, for example, cancer.
- the first aspect optionally comprises reacting the acid of Formula (VII) prepared according to the third aspect with a substituted aniline of Formula (A)
- R is selected from the group consisting of amino, hydroxy, and -NH-PG, wherein PG is an amine protecting group;
- Pv 11 is an optional substituent, for example H, halo (for example F), phenyl, optionally substituted phenyl or thienyl.
- the process also optionally comprises purifying the compound of Formula (I) so prepared.
- purification methods include recrystallization and/or titruation of the compound of Formula (I).
- said purifying comprises recrystallization.
- the process optionally comprises reacting the 4-((pyrimidin-2-yl-amino)methyl)benzoic acid of Formula (Vila) prepared according to the third aspect with a 1,2-diaminobenzene.
- the process also optionally comprises purifying the N- (2-aminophenyl)-4-((pyrimidin-2-ylamino)methyl)benzamide of Formula (la) so prepared.
- purification methods include recrystallization and/or titruation of the N-(2- aminophenyl)-4-((pyrimidin-2-ylamino)methyl)benzamide of Formula (la).
- said purifying comprises recrystallization.
- the invention comprises a process for preparing a compound of Formula (I) comprising (a) guanidinylating a compound of Formula (IV) to prepare a compound of Formula (V); (b) reacting the compound of Formula (V) so prepared with an enaminoketone of Formula (III) to yield an ester of Formula (VI); (c) converting the ester of Formula (VI) to an acid of Formula (VII); and (d) reacting the acid of Formula (VII) with a substituted aniline of Formula (A)
- R is selected from the group consisting of amino, hydroxy, and -NH-PG, wherein PG is an amine protecting group; and R 11 is an optional substituent, for example H, halo (for example F), phenyl, optionally substituted phenyl or thienyl, wherein steps (a) to (c) are performed in a "one- pot" process.
- the invention comprises a process for preparing an N-(2-aminophenyl)-4-((pyrimidin-2-ylamino)methyl)benzamides of Formula (la) comprising (a) guanidinylating a 4-((pyrimidin-2-ylamino)methyl)benzoic acid methyl ester of Formula (IVa) to prepare methyl-4-(guanidinomethyl)benzoate of Formula (Va); (b) reacting the methyl-4-(guanidinomethyl)benzoate of Formula (Va) so prepared with an enaminoketone of Formula (III) to yield a 4-((pyrimidin-2-ylamino)methyl)benzoic acid methyl ester of Formula (Via); (c) converting the 4-((pyrimidin-2-ylamino)methyl)benzoic acid methyl ester of Formula (Via) to a 4-((pyrimidin-2-yl-amino)methyl)
- the invention comprises a process for preparing a compound of Formula (I) comprising (a) guanidinylating a compound of Formula (IV) to prepare a compound of Formula (V); (b) purifiying the compound of Formula (V) so prepared; (c) reacting the purified compound of Formula (V) with an enaminoketone of Formula (III), to form an ester of Formula (VI); (d) converting the ester of Formula (VI) to an acid of Formula (VII); (e) separating the acid of Formula (VII) so prepared; and (f) reacting the acid of Formula VII) so prepared with a substituted aniline of Formula (A)
- R is selected from the group consisting of amino, hydroxy, and -NH-PG, wherein PG is an amine protecting group; and R 11 is an optional substituent, for example H, halo (for example F), phenyl, optionally substituted phenyl or thienyl, wherein steps steps (c) to (d) are performed in a "one-pot" process.
- the invention comprises a process for preparing an N-(2-aminophenyl)-4-((pyrimidin-2-ylamino)methyl)benzamide of Formula (la) comprising (a) guanidinylating a 4-((pyrimidin-2-ylamino)methyl)benzoic acid methyl ester of Formula (IVa) to prepare methyl-4-(guanidinomethyl)benzoate of Fomiula (Va); (b) purifiying the methyl-4-(guanidinometliyl)benzoate of Formula (Va) so prepared; (c) reacting the purified methyl-4-(guanidinomethyl)benzoate of Formula (Va) with an enaminoketone of Formula (III), to form a 4-((pyrimidin-2-ylamino)methyl)benzoic acid methyl ester of Formula (Via); (d) converting the 4-((pyrimidin-2-ylamino)
- the first and second aspects of the invention optionally include or further comprise salt formation of the compounds so prepared.
- the methylketone of Formula (II) is reacted with an N,N-dialkylfom amide-dialkyl acetal, for example an N,N- dimethylfomiamide-dialkyl acetal.
- an N,N-dialkylfom amide-dialkyl acetal for example an N,N- dimethylfomiamide-dialkyl acetal.
- the enaminoketone of Fomiula (III) so formed is purified prior to use in a subsequent reaction, such as, for example, by trituration with an organic solvent.
- the organic solvent can be selected (without limitation) from the group consisting of Et 2 0, MTBE, EtOAc, THF, hexane, heptane, toluene, and like, or a mixture of two or more thereof.
- the enaminoketone of Fomiula (III) is made by a process comprising reacting a methylketone of Formula (II) with a DMF acetal of the formula (R 1 )(R 2 )NCH(OR 3 )(OR 4 ), wherein R 1 and R 2 are independently a Ci.
- R 3 and R 4 are independently a Ci -4 alkyl or benzyl, (for example, R 3 and R 4 are independently selected from the group consisting of Me, Et, Pr, iso-V , Bu, tert-Bu and benzyl), in the presence of a secondary amine (such as, but not limited to Et 2 NH, Bu 2 NH, morpholine, piperidine, pyrrolidine or DBU) or a tertiary amine (such as, but not limited to, Et 3 N, DIPEA, N-methyl morpholine, N- methylpiperidine, DMAP or NN-dimethylaiiiline) and the like.
- R 1 , R 2 , R 3 and R 4 are not all Me.
- the enaminoketone of Formula (III) is optionally prepared by reacting a methylketone of Formula (II) with approximately 1.0- 6.0 equivalents, including, for example, 1.2 to 4.0 equivalents and 1.5-2.0 equivalents of DMF acetals of the formula Me 2 NCH(OR)2, where R is selected from the group consisting of Me, Et, Pr, iso-Fr, Bu, tert-Bn, benzyl and the like, in the presence of 0.5-1.5 equivalents of a tertiary amine, such as, but not limited to, Et 3 N, DIPEA, N-methyl morpholine, N-methylpiperidine, DMAP, NN-dimefhylaniline and the like, in the temperature range of 90-140°C, including, for example 110-120°C.
- the reaction may optionally proceed in a high boiling aprotic solvent such as pyridine, 1 ,2-dimethoxy e
- the enaminoketone of Formula (III) is optionally prepared by reacting a methylketone of Formula (II) with 1.5-2.0 equivalents of Me 2 NCH(OMe) 2 or Me 2 NCH(OEt) 2 in the presence of 0.5-1.5 equivalents of a tertiary amine, such as but not limited to Et 3 N, DIPEA, N-methyl morpholine, N-methylpiperidine, DMAP, NN- dimethylaniline or the like, in the temperature range of 90-140°C, including, for example, 110- 120°C.
- the reaction may optionally proceed in a high boiling aprotic solvent such as pyridine, 1 ,2-dimethoxy ethane (DME), DMSO, diphenyl ether or the like.
- an enaminoketone of Formula (III) is optionally prepared by reacting a methylketone of Formula (II) with 1.5-2.0 equivalents of Me 2 NCH(OMe) 2 or Me 2 NCH(OEt) 2 in the presence of 0.5-1.5 equivalents of Et 3 N, including, for example, equimolar quantities of Et 3 N, in the temperature range of 90-140°C, including, for example, 110-120°C.
- the reaction may optionally proceed in a high boiling aprotic solvent such as pyridine, 1 ,2-dimethoxy ethane (DME), DMSO, diphenyl ether or the like.
- the enaminoketone of Formula (III) is optionally purified prior to use in a subsequent reaction.
- the enaminoketone of Formula (III) can be purified by trituration with an organic solvent, including, without limitation, an organic solvent is selected from the group consisting of Et 2 0, MTBE, EtOAc, THF, hexane, heptane, toluene, and like, or a mixture of two or more thereof.
- an acid of Formula (VII) is prepared using a "one-pot," three-stage procedure comprising (a) guanidinylating a compound of Formula (IV) to form a compound of Formula (V); (b) reacting the compound of Formula (V) with an enaminoketone of Formula (III) under basic conditions to produce an ester of Formula (VI); and (c) hydrolyzing the ester of Formula (VI) to produce the acid of Formula (VII).
- a 4-((pyrimidin-2-yl- amino)methyl)benzoic acid of Formula (Vila) is prepared using a "one-pot," three-stage procedure comprising (a) guanidinylating a methyl 4-(aminomethyl)benzoate hydrochloride of Formula (IVa) to form 4-(guanidinomethyl)benzoate of Formula (Va); (b) reacting the 4- (guanidinomethyl)benzoate of Formula (Va) with an enaminoketone of Formula (III) under basic conditions to produce a 4-((pyrimidin-2-ylamino)methyl)benzoic acid methyl ester of Formula (Via); and (c) hydrolyzing the 4-((pyrimidin-2-ylamino)methyl)benzoic acid methyl ester of Formula (Via) to produce the 4-((pyrimidin-2-yl-amino)methyl)benzoic acid of Formula (Vila).
- preparation of a compound of Formula (V) comprises reactin a compound of Formula (IV),
- R 5 is a C 1-4 alkyl, for example methyl, with lH-pyrazole-l-carboximidamide hydrochloride or lH-l,2,4-triazole-l-carboximidamide hydrochloride (under basic conditions), or 5-methylisothiourea sulfate or cyanamide (under acidic conditions), in a solvent such as MeOH, EtOH, PrOH, wo-PrOH, THF, DME or the like (or a mixture of these solvents), at a temperature of 60-110°C, including, for example, 70 to 90 °C and 75-85 °C.
- a solvent such as MeOH, EtOH, PrOH, wo-PrOH, THF, DME or the like (or a mixture of these solvents
- the compound of Formula (V) is prepared by reacting a compound of Formula (IV), such as, for example a methyl 4- (aminomethyl)benzoate hydrochloride of Formula (IVa), with lH-pyrazole-l-carboximidamide as the guanidinylating reagent in refluxing EtOH in the presence of DIPEA (approximately 0.08- 0.15 equivalents).
- a compound of Formula (IV) such as, for example a methyl 4- (aminomethyl)benzoate hydrochloride of Formula (IVa)
- DIPEA approximately 0.08- 0.15 equivalents
- preparation of methyl-4-(guanidinomethyl)benzoate of Formula (Va) comprises reacting a methyl 4- (aminomethyl)benzoate hydrochloride of Formula (IVa), IVa)
- the methyl-4-(guanidinomethyl)benzoate of Formula (Va) is prepared by reacting methyl 4-(aminomethyl)benzoate hydrochloride of Formula (IVa), with lH-pyrazole-1- carboximidamide as the guanidinylating reagent in refluxing EtOH in the presence of DIPEA (approximately 0.08-0.15 equivalents).
- reaction of the compound of Formula (V) so prepared with an enaminoketone of Formula (III) optionally comprises (a) adding the enaminoketone of Formula (III), such as, for example, in solid form, to the compound of Formula (V) reaction mixture; (b) diluting the reaction mixture 1.5 to 4-fold with a solvent such as, but not limited to, MeOH, EtOH, PrOH, zso-PrOH, THF or DME (or a mixture of these solvents); (c) adding a solution of Li, Na, K methylates or ethylates in quantities of 1.5-4.5 equivalents; and (d) heating the reaction at approximately 60-110°C, including, for example, 75- 90 °C, for approximately 12-24 hours.
- a solvent such as, but not limited to, MeOH, EtOH, PrOH, zso-PrOH, THF or DME (or a mixture of these solvents
- a solvent such as, but not limited to, MeOH, EtOH, Pr
- Step (b) optionally comprises approximately a two-fold dilution of the reaction mixture with ethanol.
- Step (c) optionally comprises adding NaOMe in MeOH (approximately 3.0 equivalents).
- Step (d) optionally comprises heating the reaction at reflux conditions for approximately 18 hours.
- step (b) optionally comprises approximately a two-fold dilution of the reaction mixture with ethanol, step (c) comprises adding NaOMe in MeOH (approximately 3.0 equivalents), and step (d) comprises heating the reaction at reflux conditions for approximately 18 hours.
- steps (a) and (b) optionally comprise dissolving or suspending the enaminoketone of Formula (III) before addition to the reaction mixture in an amount of a solvent such as MeOH, EtOH, PrOH, z ' soPrOH, THF or DME (or a mixture of these solvents) to obtain approximately a 1.5- to 3-fold dilution of the reaction mixture.
- a solvent such as MeOH, EtOH, PrOH, z ' soPrOH, THF or DME (or a mixture of these solvents) to obtain approximately a 1.5- to 3-fold dilution of the reaction mixture.
- reaction of the 4- (guanidinomethyl)benzoate of Formula (Va) so prepared with an enaminoketone of Formula (III) optionally comprises (a) adding the enaminoketone of Formula (III), such as, for example, in solid form, to the methyl-4-(guanidinomethyl)benzoate of Formula (Va) reaction mixture; (b) diluting the reaction mixture 1.5 to 4-fold with a solvent such as, but not limited to, MeOH, EtOH, PrOH, wo-PrOH, THF or DME (or a mixture of these solvents); (c) adding a solution of Li, Na, K methylates or ethylates in quantities of 1.5-4.5 equivalents; and (d) heating the reaction at approximately 60-110°C, including, for example, 75-90°C, for approximately 12-24 hours.
- a solvent such as, but not limited to, MeOH, EtOH, PrOH, wo-PrOH, THF or DME (or a mixture of these solvents
- Step (b) optionally comprises approximately a two-fold dilution of the reaction mixture with ethanol.
- Step (c) optionally comprises adding NaOMe in MeOH (approximately 3.0 equivalents).
- Step (d) optionally comprises heating the reaction at reflux conditions for approximately 18 hours.
- step (b) optionally comprises approximately a two-fold dilution of the reaction mixture with ethanol, step (c) comprises adding NaOMe in MeOH (approximately 3.0 equivalents), and step (d) comprises heating the reaction at reflux conditions for approximately 18 hours.
- steps (a) and (b) optionally comprise dissolving or suspending the enaminoketone of Formula (III) before addition to the reaction mixture in an amount of a solvent such as MeOH, EtOH, PrOH, wo-PrOH, THF or DME (or a mixture of these solvents) to obtain approximately a 1.5- to 3 -fold dilution of the reaction mixture.
- a solvent such as MeOH, EtOH, PrOH, wo-PrOH, THF or DME (or a mixture of these solvents) to obtain approximately a 1.5- to 3 -fold dilution of the reaction mixture.
- conversion of the ester of Formula (VI) to an acid of Formula (VII) optionally comprises (a) adding to the reaction mixture approximately 1.5 - 2.0 equivalents of an aqueous solution of LiOH, NaOH or KOH, to result in a 2 to 5-fold dilution of the reaction mixture; (b) heating the reaction mixture at 80-120°C for 12-24 hours, for example at reflux conditions for approximately 18 hours; (c) cooling the reaction mixture to room temperature; (d) acidifying the reaction mixture; and (e) collecting the acid of Formula (VII).
- Step (d) optionally comprises acidification of the reaction mixture with an aqueous solution of an acid such as, but not limited to, HCOOH, AcOH, HC1, HBr, H 2 S0 4 , 3 ⁇ 4P0 4 or the like.
- the acid of Formula (VII) is collected by filtration.
- Step (a) optionally comprises adding approximately 1.6 equivalents of aqueous NaOH to the reaction mixture to obtain approximately a 3.5-fold dilution of the reaction mixture.
- Step (b) optionally comprises heating the reaction mixture at reflux conditions for approximately 18 hours.
- Step (d) optionally comprises acidification of the reaction mixture to a pH of approximately 4-7, for example 5.8.
- Step (e) optionally comprises adding an organic solvent such as, but not limited to, MeOH, EtOH, wo-PrOH, THF, acetone or the like to the acidic reaction mixture and collecting the acid of Formula (VII).
- Step (e) optionally comprises adding an organic solvent such as, but not limited to, MeOH, EtOH, iso- PrOH, THF, acetone or the like to the acidic reaction mixture, wherein the volume of the organic solvent added is approximately 0.5 to 1 times the volume of the acidified suspension, and collecting the acid of Formula (VII).
- conversion of the 4-((pyrimidin-2- ylamino)methyl)benzoic acid methyl ester of Formula (Via) to a 4-((pyrimidin-2-yl- amino)methyl)benzoic acid of Formula (Vila) optionally comprises (a) adding to the reaction mixture approximately 1.5 - 2.0 equivalents of an aqueous solution of LiOH, NaOH or KOH, to result in a 2 to 5-fold dilution of the reaction mixture; (b) heating the reaction mixture at 80- 120°C for 12-24 hours, for example at reflux conditions for approximately 18 hours; (c) cooling the reaction mixture to room temperature; (d) acidifying the reaction mixture; and (e) collecting the 4-((pyrimidin-2-yl-amino)methyl)benzoic acid of Formula (Vila).
- Step (d) optionally comprises acidification of the reaction mixture with an aqueous solution of an acid such as, but not limited to, HCOOH, AcOH, HC1, HBr, H 2 S0 4 , H 3 P0 4 or the like.
- an acid such as, but not limited to, HCOOH, AcOH, HC1, HBr, H 2 S0 4 , H 3 P0 4 or the like.
- the 4- ((pyrimidin-2-yl-amino)methyl)benzoic acid of Formula (Vila) is collected by filtration.
- Step (a) optionally comprises adding approximately 1.6 equivalents of aqueous NaOH to the reaction mixture to obtain approximately a 3.5-fold dilution of the reaction mixture.
- Step (b) optionally comprises heating the reaction mixture at reflux conditions for approximately 18 hours.
- Step (d) optionally comprises acidification of the reaction mixture to a pH of approximately 4-7, for example 5.8.
- Step (e) optionally comprises adding an organic solvent such as, but not limited to, MeOH, EtOH, z ' so-PrOH, THF, acetone or the like to the acidic reaction mixture and collecting the 4-((pyrimidin-2-yl-amino)methyl)benzoic acid of Formula (Vila).
- Step (e) optionally comprises adding an organic solvent such as, but not limited to, MeOH, EtOH, iso- ⁇ , THF, acetone or the like to the acidic reaction mixture, wherein the volume of the organic solvent added is approximately 0.5 to 1 times the volume of the acidified suspension, and collecting the 4-((pyrimidin-2-yl-amino)methyl)benzoic acid of Formula (Vila).
- reaction of the acid of Formula (VII) with a 1,2-diaminobenzene optionally comprises an amide coupling reaction of the acid of Formula (VII) with 6-12 equivalents (e.g., 8-9 equivalents) of 1 ,2-diaminobenezene in the presence of 1-3 equivalents (e.g., 1.8-2.0 equivalents) of a coupling reagent such as, but not limited to, HOBt, EDC, HATU, HBTU, BOP, DCC, DIC, CIP, PyBOP, HNTU, AOP, PPAA, PFTU, or the like (or a mixture of two or more thereof), such as, for example, a mixture of HOBt and EDC, in the presence of 2-6 equivalents, (e.g., 4.5-5.0 equivalents) of a tertiary amine such as, but not limited to, Et 3 N, DIPEA, N-methylmorpholine, N
- reaction of the 4-((pyrimidin-2- yl-amino)methyl)benzoic acid of Formula (Vila) with a 1,2-diaminobenzene optionally comprises an amide coupling reaction of the 4-((pyrimidin-2-yl-amino)methyl)benzoic acid of Formula (Vila) with 6-12 equivalents (e.g., 8-9 equivalents) of 1,2-diaminobenezene in the presence of 1-3 equivalents (e.g., 1.8-2.0 equivalents) of a coupling reagent such as, but not limited to, HOBt, EDC, HATU, HBTU, BOP, DCC, DIC, CIP, PyBOP, HNTU, AOP, PPAA, PFTU, or the like (or a mixture of two or more thereof), such as, for example, a mixture of HOBt and EDC, in the presence of 2-6 equivalents, (e.g.,
- the acid of Formula (VII) prior to reacting the acid of Formula (VII) with a 1,2-diaminobenzene, the acid of Formula (VII) is optionally converted into an activated species such as, but not limited to, an acyl halide, a mixed anhydride, a IH ⁇ imidazol-l-yl or a lH-benzo[d][l,2,3]triazol-l-yl derivative, or the like, Activation can occur, for example, in a solvent such as, but not limited to, THF, MeCN, DME, DMA or DMSO (or a mixture of such solvents) at a temperature ranging from -20° to 80°C.
- a solvent such as, but not limited to, THF, MeCN, DME, DMA or DMSO (or a mixture of such solvents) at a temperature ranging from -20° to 80°C.
- the 4-((pyrimidin-2-yl-amino)methyl)benzoic acid of Formula (Vila) prior to reacting the 4- ((pyrimidin-2-yl-amino)methyl)benzoic acid of Formula (Vila) with a 1 ,2-diaminobenzene, the 4-((pyrimidin-2-yl-amino)methyl)benzoic acid of Formula (Vila) is optionally converted into an activated species such as, but not limited to, an acyl halide, a mixed anhydride, a lH-imidazol-1- yl or a lH-benzo[d][l,2,3]triazol-l-yl derivative, or the like.
- Activation can occur, for example, in a solvent such as, but not limited to, THF, MeCN, DME, DMA or DMSO (or a mixture of such solvents) at a temperature ranging from -20° to 80°C.
- reacting the acid of Formula (VII) with a 1,2-diaminobenzene optionally comprises an amide coupling reaction of the acid of Formula (VII) with 7-10 equivalents of 1,2-diaminobenzene, in the presence of 1.0-2.5 equivalents of a mixture of HOBT and EDC, and 2.0-4.5 equivalents of Et 3 N, at a temperature of 18-25°C, in MeCN or DMSO.
- reacting the 4-((pyrimidin-2- yl-amino)methyl)benzoic acid of Formula (Vila) with a 1,2-diaminobenzene optionally comprises an amide coupling reaction of the 4-((pyrimidin-2-yl-amino)methyl)benzoic acid of Formula (Vila) with 7-10 equivalents of 1,2-diaminobenzene, in the presence of 1.0-2.5 equivalents of a mixture of HOBT and EDC, and 2.0-4.5 equivalents of Et 3 N, at a temperature of 18-25°C, in MeCN or DMSO.
- the 1,2- aminobenzene is a mono-protected 1,2-diaminobenzene of Formula (VIII) and the process optionally comprises a reaction of the acid of Formula (VII) (or an activated species thereof) with a mono-protected 1,2-diaminobenzene of Formula (VIII) (for example 1 - 2.5 equivalents):
- first and second aspects of the invention optionally a reaction of the 4-((pyrimidin-2-yl-amino)methyl)benzoic acid of Formula (Vila) (or an activated species thereof) with a mono-protected 1,2-diaminobenzene of Formula (VIII) (for example 1 - 2.5 equivalents):
- Protecting groups (PG) of the mono-protected 1,2-diaminobenzene of Formula (VIII) include, but are not limited to, tert-butoxycarbonyl (Boc), F-Moc, benzyloxycarbonyl (Cbz), -COCF 3 , -CH 2 Ph, -C(0)Me, -C(0)CF 3 or another protecting group used to protect primary amino groups ("Protective Groups in Organic Synthesis" T. W. Greene, Wiley, NY).
- protecting groups include, but are not limited to, Boc.
- Such embodiments of the first and second aspects further comprise a step of deprotection to produce the desired N-(2- aminophenyl)benzamide of Formula (I).
- the recrystallization optionally comprises (a) dissolving the compound of Formula (I) so prepared in minimal quanitities of a high boiling point solvent, such as, but not limited to, DMA, DMF, N-methylpyrrolidone, DMSO, sulfolan or the like, such as, for example DMSO, at 30-100°C, including, for example, 30-60°C; (b) filtering the solution of step (a); (c) adding to the filtrate 2-6 volumes of an anti-solvent, such as, but not limited to, MeOH, EtOH, iso-PrOH, THF, MeCN or the like, in particular EtOH or iso-PrOH; (d) solubilizing the suspension formed in step (c), for example by heating to reflux (or at 50- 90°C) and stirring, or by heating at a temperature below the boiling points of the binary solvent systems (a person
- Precipitated compound of Formula (I) can be optionally collected by suction filtration, air dried and kept in vacuum at a temperature of approximately 25-50°C for approximately 16-72 hours.
- the recrystallization optionally comprises (a) dissolving the N-(2-aminophenyl)-4-((pyrimidin-2- ylamino)methyl)benzamide of Formula (la) so prepared in minimal quanitities of a high boiling point solvent, such as, but not limited to, DMA, DMF, N-methylpyrrolidone, DMSO, sulfolan or the like, such as, for example DMSO, at 30-100°C, including, for example, 30-60°C; (b) filtering the solution of step (a); (c) adding to the filtrate 2-6 volumes
- the recrystallization optionally comprises (a) suspending the compound of Formula (I) so prepared in an approximately 1 :2 to 1 :6 mixture of a solvent such as, but not limited to, DMA, DMF, N-methylpyrrolidone, DMSO, sulfolan and like, for example DMSO, and an anti-solvent such as, but not limited to, MeOH, EtOH, iso-PrOH, THF, MeCN and the like, particularly EtOH or iso-PrOH; (b) heating the suspension at approximately 60-120°C to ensure maximal dissolution of the solids; (c) filtering the hot solution; (d) re-heating the filtrates (optionally including precipitated products) to reflux (or at 50-90°C) to ensure complete dissolution of the solids; (e) slowly cooling the solutions to a temperature of approximately -10 to 25°C; and (f
- the recrystallization optionally comprises (a) suspending the N-(2-aminophenyl)-4-((pyrimidin-2- ylamino)methyl)benzamide of Formula (la) so prepared in an approximately 1 :2 to 1 :6 mixture of a solvent such as, but not limited to, DMA, DMF, N-methylpyrrolidone, DMSO, sulfolan and like, for example DMSO, and an anti-solvent such as, but not limited to, MeOH, EtOH, iso- PrOH, THF, MeCN and the like, particularly EtOH or iso-PrOH; (b) heating the suspension at approximately 60-120°C to ensure maximal dissolution of the solids; (c) filtering the hot solution; (d) re-he
- a solvent such as, but not limited to, DMA, DMF, N-methylpyrrolidone, DMSO, sulfolan and like, for example DMSO
- an anti-solvent such as, but not limited
- the processes optionally comprises formation of pharmaceutically acceptable salts of the compound of Formula (I) by treatment of solutions or suspensions of the compound of Formula (I) with suitable acids such as HC1, HBr, HI, H 2 S0 4 , H 3 P0 4 , HN0 3 , methane sulfonic, ethane sulfonic, benzene sulfonic, p- toluene sulfonic, benzoic, lactic, succininc, salicylic, malic, citric, fumaric, maleic, glycolic, etc.; in solvents such as water, MeOH, EtOH, IP A, acetone, MTBA, 1,2-dimethoxyethane, 1,2- diethoxyethane, dioxane, THF, MeCN, EtOAc or mixtures of these solvents.
- suitable acids such as HC1, HBr, HI, H 2 S0 4 , H 3 P0 4 , HN0 3 , methane
- the processes optionally comprise formation of pharmaceutically acceptable salts of the N-(2-aminophenyl)-4- ((pyrimidin-2-ylamino)methyl)benzamide of Formula (la) by treatment of solutions or suspensions of the N-(2-aminophenyl)-4-((pyrimidin-2-ylamino)methyl)benzamide of Formula (la) with suitable acids such as HC1, HBr, HI, H 2 S0 4 , H 3 P0 4 , HN0 3 , methane sulfonic, ethane sulfonic, benzene sulfonic, p-toluene sulfonic, benzoic, lactic, succininc, salicylic, malic, citric, fumaric, glycolic, etc.; in solvents such as water, MeOH, EtOH, IP A, acetone, MTBA, 1,2- dimethoxyethane, 1,2-diethoxye
- the process of preparing an acid of Formula (VII) optionally comprises (a) providing an intermediate compound of Formula (V); (b) reacting the compound of Formula (V) with an enaminoketone of Fomiula (III) under basic conditions; and (c) collecting the acid of Formula (VII) so formed.
- the process for providing the compound of Formula (V) optionally comprises reacting a compound of Formula (IV) with 1H- pyrazole-l-carboximidamide hydrochloride or lH-l,2,4-triazole-l-carboximidamide hydrochloride under basic conditions, or S-methylisothiourea sulfate [G. Wagner et.
- Organic bases include, but are not limited to, Et 3 N, DIPEA, N-methyl morpholine, N-methylpiperidine, DMAP, NN-dimethylaniline and the like (for example, 0.2-1.2 equivalents of organic base after neutralization of the HCl associated with the hydrochlorides used).
- the reaction can be carried out at a temperature of approximately 60-110°C.
- the process for providing the compound of Formula (V) optionally comprises reacting a compound of Formula (IV) with lN-pyrazole-l-carboximidamide hydrochloride, for example in refluxing EtOH and, for example, in the presence of DIPEA (0.5-1.0 equivalents after neutralization of the HCl associated with the hydrochloride used).
- the process of preparing a 4-((pyrimidin- 2-yl-amino)methyl)benzoic acid of Formula (Vila) optionally comprises (a) providing an intermediate methyl 4-(guanidinomethyl)benzoate of Formula (Va); (b) reacting the methyl 4- (guanidinomethyl)benzoate of Formula (Va) with an enaminoketone of Formula (III) under basic conditions; and (c) collecting the 4-((pyrimidin-2-yl-amino)methyl)benzoic acid of Formula (Vila) so formed.
- the process for providing the 4-(guanidinomethyl)benzoate of Formula (Va) optionally comprises reacting a methyl 4-(aminomethyl)benzoate hydrochloride of Formula (IVa) with lH-pyrazole-l-carboximidamide hydrochloride or lN-l,2,4-triazole-l- carboximidamide hydrochloride under basic conditions, or 5-methylisothiourea sulfate [G. Wagner et. al., Pharmazie 1973, 28, 293-296] or cyanamide (under acidic conditions) in a solvent such as water, MeOH, EtOH, wo-PrOH, THF, DME (or a mixture of such solvents) or the like in the presence of an organic base.
- a solvent such as water, MeOH, EtOH, wo-PrOH, THF, DME (or a mixture of such solvents) or the like in the presence of an organic base.
- Organic bases include, but are not limited to, Et 3 N, DIPEA, N-methyl morpholine, N-methylpiperidine, DMAP, NN-dimethylaniline and the like (for example, 0.2-1.2 equivalents of organic base after neutralization of the HCl associated with the hydrochlorides used).
- the reaction can be carried out at a temperature of approximately 60- 110°C.
- the process for providing the 4-(guanidinomethyl)benzoate of Formula (Va) optionally comprises reacting a methyl 4-(aminomethyl)benzoate hydrochloride of Formula (IVa) with 1H- pyrazole-l-carboximidamide hydrochloride, for example in refluxing EtOH and, for example, in the presence of DIPEA (0.5-1.0 equivalents after neutralization of the HCl associated with the hydrochloride used).
- 1H- pyrazole-l-carboximidamide hydrochloride for example in refluxing EtOH and, for example, in the presence of DIPEA (0.5-1.0 equivalents after neutralization of the HCl associated with the hydrochloride used).
- DIPEA 0.5-1.0 equivalents after neutralization of the HCl associated with the hydrochloride used.
- Commercially available methyl 4-(aminomethyl)benzoate hydrochloride of Formula (IVa) can be used.
- the process of preparing an acid of Formula (VII) optionally comprises reacting a compound of Formula (V) with an enaminoketone of Formula (III) in a "one-pot," two stage process:
- First stage - the pyrimidine ring formation - is the reaction of an enaminoketone of Formula (III) with a compound of Formula (V) (1.0-1.5 eq.) in a solvent such as, but not limited to, MeOH, EtOH, PrOH, wo-PrOH, THF, or DME (or a mixture of two or more thereof) followed by the addition of a solution of Li, Na or K methylates or ethylates in quantities of 1.5-4.5 equivalents and heating at 40-110°C for 12-72 hours.
- the conditions are: NaOMe in MeOH (4.0 equivalents) and running the reaction at reflux conditions for 48 hours.
- Second stage - ester hydrolysis - is an addition to the reaction mixture of 1.5-5.0 equivalents of an aqueous solution of LiOH, NaOH or KOH accompanied by a 2- to 5- fold dilution of the reaction mixture with a solvent such as, but not limited to, MeOH, EtOH, PrOH, zso-PrOH, THF or DME (or a mixture two or more thereof), heating the reaction mixture at 40-120°C for 12-24 hours, followed by cooling to the room temperature, evaporating of the organics from the reaction mixture, diluting the alkaline aqueous solution with more water, washing the alkaline diluted solution with a solvent such as, but not limited to, EtOAc, toluene, MTBE, Me-THF or the like, followed by a final acidification with an aqueous acid solution such as, but not limited to, HCOOH, AcOH, HC1, HBr, H 2 S0 4 , H 3 P0 4 or the like. Acidification of the reaction mixture
- the process of preparing a 4-((pyrimidin- 2-yl-amino)methyl)benzoic acid of Formula (Vila) optionally comprises reacting a methyl 4- (guanidinomethyl)benzoate of Formula (Va) with an enaminoketone of Formula (III) in a "one- pot," two stage process:
- First stage - the pyrimidine ring formation - is the reaction of an enaminoketone of Formula (III) with a guanidine of Formula (Va) (1.0-1.5 eq.) in a solvent such as, but not limited to, MeOH, EtOH, PrOH, ⁇ -PrOH, THF, or DME (or a mixture of two or more thereof) followed by the addition of a solution of Li, Na or K methylates or ethylates in quantities of 1.5-4.5 equivalents and heating at 40-110°C for 12-72 hours.
- the conditions are: NaOMe in MeOH (4.0 equivalents) and running the reaction at reflux conditions for 48 hours,
- Second stage - ester hydrolysis - is an addition to the reaction mixture of 1.5-5.0 equivalents of an aqueous solution of LiOH, NaOH or KOH accompanied by a 2- to 5- fold dilution of the reaction mixture with a solvent such as, but not limited to, MeOH, EtOH, PrOH, wo-PrOH, THF or DME (or a mixture two or more thereof), heating the reaction mixture at 40-120°C for 12-24 hours, followed by cooling to the room temperature, evaporating of the organics from the reaction mixture, diluting the alkaline aqueous solution with more water, washing the alkaline diluted solution with a solvent such as, but not limited to, EtOAc, toluene, MTBE, Me-THF or the like, followed by a final acidification with an aqueous acid solution such as, but not limited to, HCOOH, AcOH, HC1, HBr, H 2 S0 4 , H 3 P0 4 or the like. Acidification of the reaction mixture (
- Cy is optionally substituted aryl or optionally substituted heteroaryl, for example optionally substituted heteroaryl.
- the heteroaryl can be (but is not limited to) pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl, each of which is optionally substituted.
- the heteroaryl is optionally substituted pyridinyl.
- Cy is selected from the group consisting of
- Formula (I) is an N-(2-aminophenyl)-4-((pyrimidin-2-ylamino)methyl)benzamide of Formula
- the compound of Fomiula (V) is methyl-4-(guanidinomethyl)benzoate of Fomiula (Va).
- the compound of Formula (VI) is a 4-((pyrimidin-2-ylamino)methyl)benzoic acid methyl ester of Fomiula (Via).
- the compound of Fomiula (VII) is a 4-((pyrimidin-2-yl-amino)methyl)benzoic acid of Formula (Vila).
- X is not a covalent bond.
- X is -C3 ⁇ 4-.
- Ar is p-phenyleiie.
- a disease responsive to inhibition of a histone deacetylase can be a cell proliferative disease such as, but not limited to, cancer.
- diseases responsive to inhibition of a histone deacetylase by the compounds of the invention include those selected from the group consisting of Hodgkin Lymphoma, non-Hodgkin Lymphoma, leukemia and solid tumors.
- the present invention provides an improved process of making N-(2-aminophenyl)-4- ((pyrimidin-2-ylamino)methyl)benzamides of Formula (la) and synthetic intermediates thereof.
- the invention provides an improved process to prepare N-(2-aminophenyl)-4- ((pyrimidin-2-ylamino)methyl)benzamides of Formula (la) that requires fewer steps, is efficient, can be used on an industrial scale, and results in a final product that is suitable for pharmaceutical use.
- the compounds prepared according to the present invention are suitable for methods for treating cell proliferative diseases and conditions or other diseases responsive to treatment with iV-(2-aminophenyl)-4-((pyrimidin-2-ylamiiio)methyl)benzamide compounds of Formula (la).
- R Me, Et, Pr, Bu , iso-Pr, tert-Bu , etc.
- the steps of preparing a compound of Formula (Vila) from a compound of Formula (IVa) are performed in a "one-pot" process, i.e., no isolation steps are performed during the process to prepare a compound of Formula (Vila).
- the compound of Formula III is prepared in a separate reaction, purified and then used in the process of preparing a compound of Formula (Vila) from a compound of Formula (IVa).
- the present invention further provides improved processes for preparing intermediates used in the process for preparing N-(2-aminophenyl)-4-((pyrimidin-2- ylamino)methyl)benzamides of Formula (la). Such processes are generally described in Scheme 2 and Scheme 3 :
- Scheme 3 generally describes a process to prepare a compound of Formula (Vila) according to the present invention, wherein compound of Formula (Va) is purified from a reaction used to prepare it prior to reaction with a compound of Formula (III), and wherein the process of preparing a compound of Foraiula (Vila) from the reaction of a compound of Foraiula (Va) and a compound of Formula (III) does not include the step of purifying an intermediate compound of Formula (Via) (compare Scheme 1) prior to conversion to the compound of Formula (Vila), i.e., the process of preparing a compound of Formula (Vila) from the reaction of compound of Formula (Va) and a compound of Formula (III) is a "one-pot" two-stage procedure leading to the compound of Formula (Vila).
- the invention is further related to conversion of free bases of compounds of Formula (I) into pharmaceutically acceptable salts X thereof (scheme 4).
- Suitable acids to form such salts include, without limitation, inorganic acids such as HCl, HBr, HI, H 2 S0 , H 3 P0 4 and HN0 3 , or organic acids such as methane sulfonic, ethane sulfonic, benzene sulfonic, p-toluene sulfonic, benzoic, lactic, succinic, salicylic, malic, citric, fumaric, maleic, glycolic etc, in solvents such as water, MeOH, EtOH, IP A, acetone, MTBA, 1 ,2-dimethoxyethane, 1,2-diethoxyethane, dioxane, THF, MeCN, EtOAc or mixtures of these solvents.
- salts X are made by reacting Compounds of Formula (I) (free bases) with an acid of formula HB in a solvent. Such reaction is typically conducted in two steps, though it is within the scope of this invention to simply combine both the free base and the acid in the solvent at the same time.
- the free base I is dissolved or suspended in an appropriate amount of a solvent at an appropriate temperature (typically between -10 and +20°C, alternatively between 0 and +10°C).
- an appropriate acid or a solution/suspension thereof is added to the solution (or suspension) of the free base I. It is within the skill of one of ordinary skill in the art to determine suitable amounts of acid to be used.
- the salts X precipitate from the reaction mixture and are collected by a suction filtration, rinsed with an appropriate solvent and dried. Alternatively, if the salt does not precipitate form the reaction mixture (or does not sufficiently precipitate) then the solvent is partially or completely evaporated to yield the salts X.
- the isolated salts are repurified, either by a re-crystalization from an appropriate solvent or by a trituration with an appropriate solvent.
- the isolated salts may exist as solvates or hydrates.
- references to "a compound of the formula (I), formula (II), etc.,” (or equivalently, “a compound according to the first aspect”, or “a compound of the present invention”, and the like), herein is understood to include reference to N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers, enantiomers and tautomers thereof and unless otherwise indicated.
- a bivalent linking moiety can be "alkyl,” in which case those skilled in the art will understand the alkyl to be a divalent radical (e.g., -CH 2 - CH 2 -), which is equivalent to the term “alkylene.”
- alkyl in which case those skilled in the art will understand the alkyl to be a divalent radical (e.g., -CH 2 - CH 2 -), which is equivalent to the term “alkylene.”
- aryl refers to the corresponding divalent moiety, arylene. All atoms are understood to have their normal number of valences for bond formation (i.e., 4 for carbon, 3 for N, 2 for O, and 2, 4, or 6 for S, depending on the oxidation state of the S).
- a moiety may be defined, for example, as (A) a -B-, wherein a is 0 or 1. In such instances, when a is 0 the moiety is B- and when a is 1 the moiety is A-B-. Also, a number of moietes disclosed here may exist in multiple tautomeric forms, all of which are intended to be encompassed by any given tautomeric structure.
- a C 5 -C6-heterocyclyl is a 5- or 6- membered ring having at least one heteroatom, and includes pyrrolidinyl (C 5 ) and piperidinyl (C 6 );
- C 6 -hetoaryl includes, for example, pyridyl and pyrimidyl.
- hydrocarbyl refers to a straight, branched, or cyclic alkyl, alkenyl, or alkynyl, each as defined herein.
- a “Co” hydrocarbyl is used to refer to a covalent bond.
- “Co-C 3 -hydrocarbyl” includes a covalent bond, methyl, ethyl, ethenyl, ethynyl, propyl, propenyl, propynyl, and cyclopropyl.
- aliphatic is intended to mean both saturated and unsaturated, straight chain or branched aliphatic hydrocarbons. As will be appreciated by one of ordinary skill in the art, “aliphatic” is intended herein to include, but is not limited to, alkyl, alkenyl or alkynyl moieties. [0220]
- alkyl is intended to mean a straight chain or branched aliphatic group having from 1 to 12 carbon atoms, for example 1-8 carbon atoms, and alternatively 1-6 carbon atoms. Other examples of alkyl groups have from 2 to 12 carbon atoms, alternatively 2-8 carbon atoms and alternatively 2-6 carbon atoms.
- alkyl groups include, without limitation, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl and the like.
- a "Co” alkyl (as in "C 0 -C 3 alkyl") is a covalent bond.
- alkenyl is intended to mean an unsaturated straight chain or branched aliphatic group with one or more carbon-carbon double bonds, having from 2 to 12 carbon atoms, alternatively 2-8 carbon atoms, and alternatively 2-6 carbon atoms.
- alkenyl groups include, without limitation, ethenyl, propenyl, butenyl, pentenyl, and hexenyl.
- alkynyl is intended to mean an unsaturated straight chain or branched aliphatic group with one or more carbon-carbon triple bonds, having from 2 to 12 carbon atoms, alternatively 2-8 carbon atoms, and alternatively 2-6 carbon atoms.
- alkynyl groups include, without limitation, ethynyl, propynyl, butynyl, pentynyl, and hexynyl.
- alkylene alkenylene
- alkynylene alkynylene
- alkylene groups include, without limitation, methylene, ethylene, propylene, and butylene.
- alkenylene groups include, without limitation, ethenylene, propenylene, and butenylene.
- alkynylene groups include, without limitation, ethynylene, propynylene, and butynyl ene.
- azolyl as employed herein is intended to mean a five-membered saturated or unsaturated heterocyclic group containing two or more hetero-atoms, as ring atoms, selected from the group consisting of nitrogen, sulfur and oxygen, wherein at least one of the hetero- atoms is a nitrogen atom.
- azolyl groups include, but are not limited to, optionally substituted imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,3,4-thiadiazolyl, 1 ,2,4-thiadiazolyl, 1 ,2,4-oxadiazolyl, and 1,3,4-oxadiazolyl.
- carrier as employed herein is intended to mean a cycloalkyl or aryl moiety.
- carrier also includes a cycloalkenyl moiety having at least one carbon- carbon double bond.
- cycloalkyl is intended to mean a saturated, partially unsaturated or unsaturated mono-, bi-, tri- or poly-cyclic hydrocarbon group having about 3 to 15 carbons, alternatively having 3 to 12 carbons, alternatively 3 to 8 carbons, alternatively 3 to 6 carbons, and alternatively 5 or 6 carbons.
- the cycloalkyl group is fused to an aryl, heteroaryl or heterocyclic group.
- cycloalkyl groups include, without limitation, cyclopenten-2-enone, cyclopenten-2-enol, cyclohex-2-enone, cyclohex-2-enol, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, etc.
- heteroalkyl is intended to mean a saturated or unsaturated, straight chain or branched aliphatic group, wherein one or more carbon atoms in the group are independently replaced by a moiety selected from the group consisting of O, S, N, N-alkyl, -S(O)-, -S(0) 2 -, -S(0) 2 NH-, or -NHS(0) 2 -.
- aryl is intended to mean a mono-, bi-, tri- or polycyclic aromatic moiety, for example a C 6 -C 14 aromatic moiety, for example comprising one to three aromatic rings.
- the aryl group is a C 6 -Ci 0 aryl group, for example a C 6 aryl group.
- aryl groups include, without limitation, phenyl, naphthyl, anthracenyl, and fluorenyl.
- aralkyl or "arylalkyl” are intended to mean a group comprising an aryl group covalently linked to an alkyl group. If an aralkyl group is described as “optionally substituted”, it is intended that either or both of the aryl and alkyl moieties may independently be optionally substituted or unsubstituted.
- the aralkyl group is (C 1 -C 6 )alk(C6-C 1 o)aryl, including, without limitation, benzyl, phenethyl, and naphthylmethyl.
- arylalkyl this term, and terms related thereto, is intended to indicate the order of groups in a compound as “aryl - alkyl”.
- alkyl-aryl is intended to indicate the order of the groups in a compound as “alkyl-aryl”.
- heterocyclyl is intended to mean a group which is a mono-, bi-, or polycyclic structure having from about 3 to about 14 atoms, wherein one or more atoms are independently selected from the group consisting of N, O, and S.
- the ring structure may be saturated, unsaturated or partially unsaturated.
- the heterocyclic group is non-aromatic, in which case the group is also known as a heterocycloalkyl.
- the heterocyclic group is a bridged heterocyclic group (for example, a bicyclic moiety with a methylene, ethylene or propylene bridge).
- one or more rings may be aromatic; for example one ring of a bicyclic heterocycle or one or two rings of a tricyclic heterocycle may be aromatic, as in indan and 9,10- dihydro anthracene.
- heterocyclic groups include, without limitation, epoxy, aziridinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, thiazolidinyl, oxazolidinyl, oxazolidinonyl, and morpholino.
- the heterocyclic group is fused to an aryl, heteroaryl, or cycloalkyl group.
- fused heterocycles include, without limitation, tetrahydroquinoline and dihydrobenzofuran. Specifically excluded from the scope of this term are compounds where an annular O or S atom is adjacent to another O or S atom.
- the heterocyclic group is a heteroaryl group.
- heteroaryl is intended to mean a mono-, bi-, tri- or polycyclic group having 5 to 18 ring atoms, including 5 to 14 ring atoms (e.g., 5, 6, 9, or 10 ring atoms) and, for example, having 6, 10, or 14 pi electrons shared in a cyclic array; and having, in addition to carbon atoms, between one or more heteroatoms selected from the group consisting of N, O, and S.
- heteroaryl is also intended to encompass the N-oxide derivative (or N-oxide derivatives, if the heteroaryl group contains more than one nitrogen such that more than one N-oxide derivative may be formed) of a nitrogen-containing heteroaryl group.
- a heteroaryl group may be pyrimidinyl, pyridinyl, benzimidazolyl, thienyl, benzothiazolyl, benzofuranyl and indolinyl.
- heteroaryl groups include, without limitation, thienyl, benzothienyl, furyl, benzofuryl, dibenzofuryl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, indolyl, quinolyl, isoquinolyl, quinoxalinyl, tetrazolyl, oxazolyl, thiazolyl, isoxazolyl, benzo[b]thienyl, naphtha[2,3-b]thianthrenyl, zanthenyl, quinolyl, benzothiazolyl, benzimidazolyl, beta-carbolinyl and perimidinyl.
- N-oxide derivatives of heteroaryl groups include, but are not limited to, pyridyl N-oxide, pyrazinyl N-opxide, pyrimidinyl N-oxide, pyridazinyl N-oxide, triazinyl N-oxide, isoquinolyl N-oxide and quinolyl N-oxide.
- arylene is intended to mean an aryl, heteroaryl, or heterocyclyl group, respectively, as defined hereinabove, that is positioned between and serves to connect two other chemical groups.
- a heteroalicyclic group refers specifically to a non-aromatic heterocyclyl radical.
- a heteroalicyclic may contain unsaturation, but is not aromatic.
- a heterocyclylalkyl group refers to a residue in which a heterocyclyl is attached to a parent structure via one of an alkylene, alkylidene, or alkylidyne radical.
- Examples include (4- methylpiperazin-l-yl) methyl, (morpholin-4-yl) methyl, (pyridine-4-yl) methyl,2- (oxazolin-2-yl) ethyl,4- (4-methylpiperazin-l-yl)-2-butenyl, and the like.
- heterocyclylalkyl is described as “optionally substituted” it is meant that both the heterocyclyl and the corresponding alkylene, alkylidene, or alkylidyne radical portion of a heterocyclylalkyl group may be optionally substituted.
- a “lower heterocyclylalkyl” refers to a heterocyclylalkyl where the “alkyl” portion of the group has one to six carbons.
- a heteroalicyclylalkyl group refers specifically to a heterocyclylalkyl where the heterocyclyl portion of the group is non-aromatic.
- heterocyclyls and heteroaryls include, but are not limited to, azepinyl, azetidinyl, acridinyl, azocinyl, benzidolyl, benzimidazolyl, benzofuranyl, benzofurazanyl, benzofuryl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzothienyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolmyl, benzoxazolyl, benzoxadiazolyl, benzopyranyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, coumarinyl, decahydroquinolinyl, dibenzofuryl, 1,3-
- halohydrocarbyl as employed herein is a hydrocarbyl moiety, in which from one to all hydrogens have been replaced with an independently selected halo.
- Suitable substituents include, without limitation, halo, hydroxy, oxo (e.g., an annular -CH- substituted with oxo is -C(O)-) nitro, halohydrocarbyl, hydrocarbyl, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, alkoxy, aryloxy, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl, acyl, carboxy, hydroxyalkyl, alkanesulfonyl, arenesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano, and ureido grotips.
- substituents which are themselves not further substituted (unless expressly stated otherwise) are:
- R 32 and R 33 are each independently hydrogen, halo, hydroxyl or Q-Qalkyl, and R and R are each independently hydrogen, cyano, oxo, hydroxyl, Q-Cgalkyl, Ci-Cgheteroalkyl, Cj-Cgalkenyl, carboxamido, CrQalkyl-carboxamido, carboxamido-Q-Qalkyl, amidino, C 2 - Qhydroxyalkyl, CrQalkylaryl, aryl-Ci-C 3 alkyl, Ci-C3alkylheteroaryl, heteroaryl-Ci-C 3 alkyl, Q-Qalkylheterocyclyl, heterocyclyl-Ci-C 3 alkyl C ⁇ - C 3 alkylcycl
- aryloxycarbonyl aryl-Ci-Csalkoxycarbonyl, heteroaryloxycarbonyl, heteroaryl-Ci-Csalkoxycarbonyl, Ci-Cgacyl, Co-C 8 alkyl- carbonyl, aryl-Co-C 8 alkyl-carbonyl, heteroaryl-Co-C 8 alkyl-carbonyl, cycloalkyl- Co-Cgalkyl-carbonyl, heterocyclyl-Co-C 8 alkyl-carbonyl, Co-Csalkyl-NH-carbonyl, aryl-Co-Csalkyl-NH-carbonyl, heteroaryl-Co-C 8 alkyl-NH-carbonyl, cycloalkyl-Co- Cgalkyl-NH-carbonyl, heterocylclyl-Co-C 8 alkyl-NH-carbonyl, cycloalkyl-S(0) 2 -, heterocyclyl-S(0) 2 -, aryl-S
- X is selected from the group consisting of H, Q-Cgalkyl, C 2 -Cgalkenyl-, C 2 - Qalkynyl-, -C 0 -C 3 alkyl-C 2 -C 8 alkenyl-C 0 -C 3 alkyl, C 0 -C 3 alkyl-C 2 -C 8 alkynyl- C 0 -C 3 alkyl, C 0 -C 3 alkyl-O-C 0 -C 3 alkyl-, HO-C 0 -C 3 alkyl-, C 0 -C 4 alkyl-N(R 30 )- C 0 -C 3 alkyl-, N(R 30 )(R 31 )-C 0 -C 3 alkyl-, N(R 30 )(R 31 )-C 0 -C 3 alkenyl-, N(R 30 )(R 31 )-C 0 -C 3 alkynyl
- Y 31 is selected from the group consisting of a direct bond, -0-, -N(R 30 )-, -C(O)-, -O-C(O)-, -C(0)-0-, -N(R 30 )-C(O)-, -C(0)-N(R 30 )-, -N(R 30 )-C(S)-, -C(S)- N(R 30 )-, -N(R 30 )-C(O)-N(R 31 )-, -N(R 30 )-C(NR 30 )-N(R 31 )-, -N(R 30 )-C(NR 31 )-, -C(NR 31 )-N(R 30 )-, -N(R 30 )-C(S)-N(R 31 )-, -N(R 30 )-C(O)-O-, -0-C(0)-N(R 31 )-, -N(R 30 )
- a moiety that is substituted is one in which one or more (e.g., one to four, one to three, or and one or two), hydrogens have been independently replaced with another chemical substituent.
- substituted phenyls include 2-flurophenyl, 3,4- dichlorophenyl, 3-chloro-4-fluoiO-phenyl, 2-fluoro-3-propylphenyl.
- substituted n-octyls include 2,4-dimethyl-5-ethyl-octyl and 3-cyclopentyl-octyl. Included within this definition are methylenes (-C3 ⁇ 4-) substituted with oxygen to form carbonyl -CO-.
- a group, such as a hydrocarbyl, heteroalkyl, heterocyclic and/or aryl group can be unsubstituted. Or a group, such as a hydrocarbyl, heteroalkyl, heterocyclic and/or aryl group can be substituted with from 1 to 4 (e.g., one to three, or one or two) independently selected substituents.
- alkenyl and alkynyl groups include, but are not limited to, alkyl or substituted alkyl, as well as those groups recited as examples of alkyl substituents.
- substituents on cycloalkyl groups include, but are not limited to, nitro, cyano, alkyl or substituted alkyl, as well as those groups recited above as examples of alkyl substituents.
- substituents include, but are not limited to, spiro-attached or fused cyclic substituents, for example spiro-attached cycloalkyl, spiro-attached cycloalkenyl, spiro-attached heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle and aryl substituents can themselves be optionally substituted.
- a cycloalkyl when substituted by two C 1-6 alkyl groups, the two alkyl groups may combine together to form an alkylene chain, for example a C 1-3 alkylene chain.
- Cycloalkyl groups having this crosslinked structure include bicyclo[2.2.2]octanyl and norbornanyl.
- substituents on cycloalkenyl groups include, but are not limited to, nitro, cyano, alkyl or substituted alkyl, as well as those groups recited as examples of alkyl substituents.
- substituents include, but are not limited to, spiro-attached or fused cyclic substituents, especially spiro-attached cycloalkyl, spiro-attached cycloalkenyl, spiro- attached heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle and aryl substituents can themselves be optionally substituted.
- the two alkyl groups may combine together to form an alkylene chain, for example a C
- substituents on aryl groups include, but are not limited to, nitro, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, cyano, alkyl or substituted alkyl, as well as those groups recited above as examples of alkyl substituents.
- substituents include, but are not limited to, fused cyclic groups, especially fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, where the aforementioned cycloalky, cylcoalkenyl, heterocycle and aryl substituents can themselves be optionally substituted.
- substituents on aryl groups include, but are not limited to, haloalkyl and those groups recited as examples of alkyl substituents.
- substituents on aryl groups include, but are not limited to, haloalkyl and those groups recited as examples of alkyl substituents.
- the two alkyl groups may combine together to form an alkylene chain, for example a C 1-3 alkylene chain.
- substituents on heterocyclic groups include, but are not limited to, spiro- attached or fused cylic substituents at any available point or points of attachement, for example spiro-attached cycloalkyl, spiro-attached cycloalkenyl, spiro-attached heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloakenyl, fused heterocycle and fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle and aryl substituents can themselves be optionally substituted.
- the two alkyl groups may combine together to form an alkylene chain, for example a C 1-3 alkylene chain.
- a heterocyclic group can be optionally substituted on carbon, nitrogen and/or sulfur at one or more positions.
- substituents on carbon include those groups recited as examples of alkyl substituents.
- substituents on nitrogen include, but are not limited to alkyl, aryl, aralkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, alkoxycarbonyl, or aralkoxycarbonyl.
- substituents on sulfur include, but are not limited to, oxo and Ci -6 alkyl. Nitrogen and sulfur heteroatoms may independently be optionally oxidized and nitrogen heteroatoms may independently be optionally quaternized.
- Substituents on ring groups include halogen, alkoxy and alkyl.
- Substituents on alkyl groups include halogen and hydroxy.
- halogen refers to chlorine, bromine, fluorine, or iodine.
- acyl refers to an alkylcarbonyl or arylcarbonyl substituent.
- acylamino refers to an amide group attached at the nitrogen atom (i.e., R-CO-NH-).
- carbamoyl refers to an amide group attached at the carbonyl carbon atom (i.e., NH 2 -CO-).
- the nitrogen atom of an acylamino or carbamoyl substituent is additionally optionally substituted.
- sulfonamido refers to a sulfonamide substituent attached by either the sulfur or the nitrogen atom.
- amino is meant to include NH 2 , alkylamino, di-alkyl-amino (wherein each alkyl moiety may be the same or different), arylamino, and cyclic amino groups.
- ureido refers to a substituted or unsubstituted urea moiety.
- radical means a chemical moiety comprising one or more unpaired electrons.
- substituents on cyclic moieties include 5- to 6-membered mono- and 9- to 14-membered bi-cyclic moieties fused to the parent cyclic moiety to form a bi- or tri-cyclic fused ring system.
- substituents on cyclic moieties also include 5- to 6-membered mono- and 9- to 14-membered bi-cyclic moieties attached to the parent cyclic moiety by a covalent bond to form a bi- or tri-cyclic bi-ring system.
- an optionally substituted phenyl includes, but is not limited to, the following:
- a saturated or unsaturated three- to eight-membered carbocyclic ring includes, for example, a four- to seven-membered and a five- or six-membered, saturated or unsaturated carbocyclic ring.
- saturated or unsaturated three- to eight-membered carbocyclic rings include phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
- a saturated or unsaturated three- to eight-membered heterocyclic ring contains at least one heteroatom selected from oxygen, nitrogen, and sulfur atoms. So, for example, the saturated or unsaturated three- to eight-membered heterocyclic ring can contain one or two Iieteroatoms with the remaining ring- constituting atoms being carbon atoms.
- the saturated or unsaturated three- to eight-membered heterocyclic ring can also be a saturated or unsaturated four- to seven-membered heterocyclic ring or a saturated or unsaturated five- or six-membered heterocyclic ring.
- saturated or unsaturated three- to eight-membered heterocyclic groups include thienyl, pyridyl, 1,2,3-triazolyl, imidazolyl, isoxazolyl, pyrazolyl, piperazinyl, piperazino, piperidyl, piperidino, morpholinyl, morpholino, homopiperazinyl, homopiperazino, thiomorpholinyl, thiomorpholino, tetrahydropyrrolyl, and azepanyl.
- salt(s) denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases.
- a compound of Formula (I) contains both a basic moiety, such as but not limited to a pyridine or imidazole, and an acidic moiety such as but not limited to a carboxylic acid, zwitterions ("inner salts”) may be formed and are included within the term “salt(s)” as used herein.
- Pharmaceutically acceptable (i.e., non-toxic (exhibiting minimal or no undesired toxicological effects), physiologically acceptable) salts are one example, although other salts are also useful, e.g., in isolation or purification steps which may be employed during preparation.
- Salts of the compounds of the invention may be formed, for example, by reacting a compound of the present invention with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salts precipitates or in an aqueous medium followed by lyophilization.
- the compounds of the present invention which contain a basic moiety may form salts with a variety of organic and inorganic acids.
- Exemplary acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acid, for example, trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides, hydrobromides, hydroiodides,
- the compounds of the present invention which contain an acidic moiety may form salts with a variety of organic and inorganic bases.
- Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as benzathines, dicyclohexylamines, hydrabamines (formed with N,N-bis(dehydroabietyl) ethylenediamine), N-methyl-D-glucamines, N-methyl-D-glycamides, t-butyl amines, and salts with amino acids such as arginine, lysine and the like.
- Basic nitrogen- containing groups may be quaternized with agents such as lower alkyl halides (e.g. methyl, ethyl, propyl and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, dibuty and diamyl sulfates), long chain halides (e.g. decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.
- lower alkyl halides e.g. methyl, ethyl, propyl and butyl chlorides, bromides and iodides
- dialkyl sulfates e.g. dimethyl, diethyl, dibuty and diamyl sulfates
- long chain halides e.g
- salts are intended to mean salts that retain the desired biological activity of the above-identified compounds and exhibit minimal or no undesired toxicological effects.
- compositions including a compound, N- oxide, hydrate, solvate, pharmaceutically acceptable salt, complex or prodrug of a compound according to the present invention as described herein, or a racemic mixture, diastereomer, enantiomer or tautomer thereof.
- a composition comprises a compound, N-oxide, hydrate, solvate, pharmaceutically acceptable salt, complex or prodrug of a compound according to the present invention as described herein present in at least about 30% enantiomeric or diastereomeric excess.
- the compound, N-oxide, hydrates, solvate, pharmaceutically acceptable salt, complex or prodrug is present in at least about 50%, at least about 80%, or even at least about 90% enantiomeric or diastereomeric excess. In certain embodiments of the invention, the compound, N-oxide, hydrate, solvate, pharmaceutically acceptable salt, complex or prodrug is present in at least about 95%, at least about 98%, or at least about 99% enantiomeric or diastereomeric excess. In certain embodiments of the invention, a compound, N-oxide, hydrate, solvate, pharmaceutically acceptable salt, complex or prodrug is present as a substantially racemic mixture.
- the terms "protect”, “protected”, and “protecting” are intended to refer to a process in which a functional group in a chemical compound is selectively masked by a non-reactive functional group in order to allow a selective reaction(s) to occur elsewhere on said chemical compound.
- Such non-reactive functional groups are herein termed "protecting groups”.
- nitrogen protecting group is intended to mean a group capable of selectively masking the reactivity of a nitrogen (N) group.
- suitable protecting group is intended to mean a protecting group useful in the preparation of the compounds of the present invention. Such groups are generally able to be selectively introduced and removed using mild reaction conditions that do not interfere with other portions of the subject compounds.
- These protecting groups may be removed at a convenient stage using methods known from the art.
- anti-solvent refers to a fluid that is added to a solution, which comprises at least one solvent and at least one solute, to cause the solubility of the solute in the solvent to decrease.
- An anti-solvent can be especially useful to decrease the solubility of the solute to such a point that at least some of the solute precipitates from the solution.
- purification refers to a process in which the purity of a desired compound is increased. It also refers to a process in which the percentage of a desired compound in a mixture is increased as a result of such process. Purification may be performed in a single reaction vessel, or in a multitude of reaction vessels.
- purification examples include: dissolving and filtering off impurities away from a mixture comprising both the desired compound and impurities; dissolving preferentially with a solvent the desired compound from a mixture comprising both the desired compound and impurities to generate a solution, followed by filtering of the solution, and isolating the desired compound by evaporation of the solvent or crystallization of the desired compound; re-crystallization of the desired compound; and the use of chromatography of the mixture comprising impurities and the desired compound.
- purified compound refers to a desired compound which has gone through a purification process.
- one-pot process refers to a process, or a part of a process, in which a compound is subjected to successive chemical reactions in just one reactor vessel.
- one-pot process refers to a process in which there is no separation or purification of an intermediate compound.
- reaction mixture was then cooled to 50°C, quickly transferred to a 3L one-neck round-bottom flask and evaporated under reduced pressure to afford a brownish solid, which was then immediately re-suspended in a mixture of MTBE (290 mL, drum grade) and hexane (290 mL, HPLC grade).
- MTBE 290 mL, drum grade
- hexane 290 mL, HPLC grade
- the resultant suspension was stirred at room temperature for 24-72 hours. The progress of the reaction was monitored by NMR or HPLC for the disappearance of the acid 3.
- the precipitate was collected by suction filtration and washed with acetonitrile (4 x 250 mL), water (4 x 250 mL), and MTBE (2 x 200 mL), to afford a material which was triturated with MeOH at reflux for 18 hours.
- the resultant slurry was filtered at 50°C and washed with MeOH (2 x 50 mL) to produce after drying the title compound 4 (132-150g, 66-75% yield).
- a 2L, three-neck round bottom flask equipped with a thermometer, nitrogen inlet and a mechanical stirrer was charged with material derived in the Example 6 (42.04 g) followed by DMSO (126 mL) at room temperature.
- the suspension was heated to 45°C over 20 min to allow for the dissolution of the solid.
- the solution was stirred for an additional 15 min then cooled to 25-30°C, stirred for another 15 min at the same conditions and suction filtered.
- the filter was rinsed with DMSO (42 mL), the filtrate and washings were combined and transferred into another 2L, three-neck round bottom flask equipped with a thermometer, nitrogen inlet, a mechanical stirrer, a reflux condenser and an addition funnel.
- HCl (31%w/w) (6.4 mL) was added over a period of 1 minute under vigorous agitation to dissolve the solids.
- the solution was quickly filtered, the pH was adjusted to 7 - 9 using NaOH (2.5N) (31.2 mL) while maintaining agitation for 30 min at 0-5 °C.
- a precipitate was formed which was collected by filtration, rinsed with deionized water (60 mL) in three portions and ethanol (40 mL) in two portions.
- the filter cake was air-dried followed by drying in a vacuum oven at 20-25 °C for 10 minutes then re-suspended in ethanol (150 mL).
- the temperature of the suspension was adjusted to 0-5 °C.
- Hydrobromic acid (48%w/w) (6.2 mL) was added to the suspension over 1 minute maintaining the temperature at 0-5 °C.
- the suspension was stirred at the same temperature with moderate agitation for an additional 3 hours then filtered.
- the filter cake was rinsed with ethanol (40 mL) in two portions and then heptane (40 mL) in two portions.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Cette invention concerne un procédé amélioré de production de composés de formule (I) et de leurs intermédiaires synthétiques. En particulier, l'invention concerne un procédé amélioré de préparation de N-(2-aminophényl)-4- ((pyrimidin-2-ylamino)méthyl)benzamides qui nécessite peu d'étapes, est efficace, peut être utilisé à l'échelle industrielle, et donne lieu à un produit final qui est approprié à une utilisation pharmaceutique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361847773P | 2013-07-18 | 2013-07-18 | |
US61/847,773 | 2013-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015006875A1 true WO2015006875A1 (fr) | 2015-01-22 |
Family
ID=52345660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2014/050684 WO2015006875A1 (fr) | 2013-07-18 | 2014-07-18 | Procédé de préparation de pyrimidines substituées |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015006875A1 (fr) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018213329A1 (fr) | 2017-05-15 | 2018-11-22 | Blueprint Medicines Corporation | Associations d'inhibiteurs de ret et d'inhibiteurs de mtorc1, et utilisations de celles-ci pour le traitement de cancers liés à une activité ret aberrante |
US10183928B2 (en) | 2016-03-17 | 2019-01-22 | Blueprint Medicines Corporation | Inhibitors of RET |
US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
US10584114B2 (en) | 2015-11-02 | 2020-03-10 | Blueprint Medicines Corporation | Inhibitors of RET |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US11273160B2 (en) | 2018-04-03 | 2022-03-15 | Blueprint Medicines Corporation | RET inhibitor for use in treating cancer having a RET alteration |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
US11427567B2 (en) | 2019-08-14 | 2022-08-30 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
US11851426B2 (en) | 2019-10-11 | 2023-12-26 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004035525A1 (fr) * | 2002-10-17 | 2004-04-29 | Methylgene Inc. | Inhibiteurs de l'histone deacetylase |
US20040142953A1 (en) * | 2001-09-14 | 2004-07-22 | Methylgene, Inc. | Inhibitors of histone deacetylase |
WO2005092899A1 (fr) * | 2004-03-26 | 2005-10-06 | Methylgene Inc. | Inhibiteurs d'histone désacétylase |
WO2008113255A1 (fr) * | 2007-03-16 | 2008-09-25 | The Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla | Dérivés de benzamide avec activité antiproliférative, leurs préparations pharmaceutiques |
CN103204851A (zh) * | 2012-01-12 | 2013-07-17 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 含稠杂环基的苯甲酰胺类衍生物及其治疗用途 |
-
2014
- 2014-07-18 WO PCT/CA2014/050684 patent/WO2015006875A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040142953A1 (en) * | 2001-09-14 | 2004-07-22 | Methylgene, Inc. | Inhibitors of histone deacetylase |
WO2004035525A1 (fr) * | 2002-10-17 | 2004-04-29 | Methylgene Inc. | Inhibiteurs de l'histone deacetylase |
WO2005092899A1 (fr) * | 2004-03-26 | 2005-10-06 | Methylgene Inc. | Inhibiteurs d'histone désacétylase |
WO2008113255A1 (fr) * | 2007-03-16 | 2008-09-25 | The Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla | Dérivés de benzamide avec activité antiproliférative, leurs préparations pharmaceutiques |
CN103204851A (zh) * | 2012-01-12 | 2013-07-17 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 含稠杂环基的苯甲酰胺类衍生物及其治疗用途 |
Non-Patent Citations (4)
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
US10774070B2 (en) | 2015-02-06 | 2020-09-15 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
US10584114B2 (en) | 2015-11-02 | 2020-03-10 | Blueprint Medicines Corporation | Inhibitors of RET |
US11279688B2 (en) | 2015-11-02 | 2022-03-22 | Blueprint Medicines Corporation | Inhibitors of RET |
US10183928B2 (en) | 2016-03-17 | 2019-01-22 | Blueprint Medicines Corporation | Inhibitors of RET |
US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
WO2018213329A1 (fr) | 2017-05-15 | 2018-11-22 | Blueprint Medicines Corporation | Associations d'inhibiteurs de ret et d'inhibiteurs de mtorc1, et utilisations de celles-ci pour le traitement de cancers liés à une activité ret aberrante |
US11963958B2 (en) | 2018-04-03 | 2024-04-23 | Rigel Pharmaceuticals, Inc. | RET inhibitor for use in treating cancer having a RET alteration |
US11273160B2 (en) | 2018-04-03 | 2022-03-15 | Blueprint Medicines Corporation | RET inhibitor for use in treating cancer having a RET alteration |
US11872192B2 (en) | 2018-04-03 | 2024-01-16 | Blueprint Medicines Corporation | RET inhibitor for use in treating cancer having a RET alteration |
US11866432B2 (en) | 2018-10-11 | 2024-01-09 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
US11427567B2 (en) | 2019-08-14 | 2022-08-30 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors |
US11851426B2 (en) | 2019-10-11 | 2023-12-26 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015006875A1 (fr) | Procédé de préparation de pyrimidines substituées | |
EP3761980B1 (fr) | Composés d'acides aminés et leurs procédés d'utilisation | |
US8338437B2 (en) | Amines as small molecule inhibitors | |
JP6787998B2 (ja) | 置換3−(3−アニリノ−1−シクロヘキシル−1h−ベンズイミダゾール−5−イル)プロパン酸誘導体を調製する方法 | |
EP2217588A1 (fr) | Inhibiteurs de l'histone déacétylase | |
JP7157764B2 (ja) | 新規なピペリジン-2,6-ジオン誘導体及びその用途 | |
CA2695628A1 (fr) | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met | |
WO2013006792A1 (fr) | Composés antiviraux | |
WO2009026701A1 (fr) | Inhibiteurs de sirtuine | |
CA3054324C (fr) | Compose a trois cycles et ses applications | |
US8921550B2 (en) | Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives | |
CN115109078A (zh) | 嘧啶并吡啶类抑制剂及其制备方法和应用 | |
WO2011069118A1 (fr) | Modulateurs de ship1 et méthodes associées | |
JP4268871B2 (ja) | ピリミジノン化合物及びその薬剤として許容される塩の製造方法 | |
WO2007039580A1 (fr) | Composes de benzophenone substitues par imidazolyle | |
CA2714966A1 (fr) | Heterocycles d'arylmethylidene comme nouveaux analgesiques | |
CA2399377C (fr) | Nouveaux modulateurs (paarm) allosteriques positifs de recepteurs ampa, leur methode de production et leur utilisation comme medicaments | |
AU2015316719A1 (en) | Imidazo[2,1-b]thiazole and 5,6-dihydroimidazo[2,1-b]thiazole derivatives useful as S100-inhibitors | |
KR101941794B1 (ko) | 아미노설포닐계 화합물, 이의 제조 방법 및 용도 | |
CN115160321B (zh) | 一种伐地那非类似物及其合成方法和应用 | |
KR20120129317A (ko) | 헤테로고리 화합물의 제조방법 | |
AU2008318244B2 (en) | Inhibitors of histone deacetylase | |
CA3220329A1 (fr) | Composes anticancereux | |
FR2919870A1 (fr) | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet | |
AU2013204436A1 (en) | Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14826287 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14826287 Country of ref document: EP Kind code of ref document: A1 |